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Abstract 
 
Risk factors such as intrauterine and vaginal infection put pregnant women at risk for delivering 
preterm. Bacterial vaginosis (BV) is a polymicrobial clinical syndrome commonly diagnosed in women 
of reproductive age, with women of African descent with low socioeconomic status and previous 
preterm delivery at high risk. Although frequently isolated from healthy women, Gardnerella vaginalis 
has been most frequently associated with BV. There is limited data available on the prevalence of BV in 
Southern Africa; therefore, we embarked on a study to determine the prevalence of BV and G. vaginalis 
in predominantly black communities in the Western Cape, in order to establish the role of G. vaginalis 
in BV. 
 
Women attending various Maternity and Obstetrics units (MOU) in the Cape Peninsula with and without 
a history of pre-term delivery (PTD) were invited to participate in the study. Several factors were 
statistically associated with pregnancy history, including location of study population, parity, smoking 
and presence of clinical symptoms. The presence of G. vaginalis was determined by culture in 51.7% of 
the preterm delivery group (PTDG) and 44% of the full-term delivery group (FTDG) women. BV was 
detected in 31.13% of PTDG and 23.67% of FTDG by Gram stained analysis according to Nugent 
scoring criteria, with age and HIV status posing as risk factors. When comparing PTDG and FTDG for 
an association between the presence of G. vaginalis and BV, a stronger association was observed in the 
PTDG but it was not statistically significant. In both PTDG and FTDG, G. vaginalis was isolated 
significantly more often in women diagnosed with BV at 24.5% (p < 0.05). Antibiogram studies 
revealed both Metronidazole and Clindamycin resistant strains of G. vaginalis. G. vaginalis Biotype 7 is 
specifically associated with BV, while Biotype 2 appears to be associated with BV in women with a 
history of PTD.  Accuracy of diagnostic tools were tested and it was determined that Nugent scoring is 
more sensitive in diagnosing BV (76.04%), but culture for G. vaginalis is more specific (83.21%). 
 
Although this study was limited in that we were unable to follow-up pregnancy outcomes, we were able 
to confirm the perceived role of G. vaginalis in BV.  
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 Chapter 1: Introduction & literature review 
 
1.1.  BACKROUND 
Infections account for 10-30% of cases of preterm labour (PTL; Dudley, 1997). There are numerous 
organisms that can cause intrauterine infection, including Ureaplasma urealyticum, Mycoplasma 
hominis, Gardnerella vaginalis, Peptostreptococcus and Bacteroides species. Viral infection, although 
uncommon, may also cause spontaneous preterm delivery (PTD; Goldenberg et al., 2000; Haas et al., 
2005) by either haematogenous spread or ascension from the genital tract (Pereira et al., 2005). 
There are four stages to ascending intra-uterine infection. The first stage commences when there is a 
change in vaginal and cervical flora, or presence of cervical pathogens. Bacterial vaginosis (BV) usually 
manifests in this initial stage. This is succeeded by micro-organisms gaining access to the intrauterine 
cavity, enabling them to take up residence in the deciduas. The infection may invade foetal vessels or 
enter the amnion, resulting in microbial invasion of the amniotic cavity or an intra-amniotic infection 
(stage 3). Finally, bacteria may enter the foetus through various ports, initiating PTL (Romero et al., 
2003). 
 
1.2. THE NORMAL VAGINAL ECOSYSTEM  
The female genital tract is a complex and dynamic entity that is colonised by an array of different 
microbiological organisms. The vaginal ecosystem is balanced and controlled by the microbial 
community that inhabits it. Hormonal and developmental changes may occur due to age, stage of 
menstrual cycle, pregnancy, method of contraception, frequency of sexual intercourse, number of sexual 
partners, vaginal douching, use of panty-liners or vaginal deodorants and infection.  Similarly, there 
seems to be differences in the composition of normal vaginal microbiota among different racial/ethnic 
groups (Larsen & Monif, 2001; Hay, 2002; Zhou et al., 2004; Witkin et al., 2007).  
 
A healthy vaginal ecosystem is dominated by lactic acid and hydrogen peroxide (H2O2)-producing 
Lactobacillus species. Lactobacillus acidophilus was thought to be the predominant species found in the 
normal vaginal flora. However, recent studies have shown that L. crispatus, L. iners, L. gasseri, L. 
jensenii, L. vaginalis and L. gallinarum may also be present. While the healthy vagina is highly 
populated by Lactobacillus species, several other species, such as Staphylococcus, Ureaplasma, 
Gardnerella, Corynebacterium, Streptococcus, Peptrostreptococcus, Bacteroides, Mycoplasma, 
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Enterococcus, Escherichia, Veilonella, Bifidobacterium and Candida, are present in reduced 
concentrations (Zhou et al., 2004). 
 
The presence of Lactobacilli helps to preserve a healthy vagina, as it maintains its acidic environment, 
which acts as a protective mechanism preventing the proliferation of microbial pathogens and the 
development and transmission of infectious conditions such as sexually transmitted infections (STIs; 
Pavlova et al., 2002; Wilks et al., 2004; Zhou et al., 2004; Donders, 2007; Witkin et al., 2007; Turovskiy 
et al., 2011). 
Elevated oestrogen levels during puberty results in an increase in glycogen content in vaginal epithelial 
cells. Glycogen promotes the growth of the beneficial Lactobacilli while simultaneously preventing the 
growth of potential pathogens. In addition, glycogen metabolism yields lactic acid, promoting a 
preferred vaginal pH of 3.5-4.5. The moment there is a reduction in Lactobacilli concentration, the 
vaginal pH increases to approximately 7.0, enabling BV-associated organisms to thrive with a 1000-fold 
increase in concentrations (Wang, 2000; Hay, 2005; Turovskiy et al., 2011). In cases where Lactobacilli 
species are unable to thrive, they may be replaced by other lactic acid producing organisms, such as 
Atopobium vaginae, Megasphaera species and Leptotrichia species.  
 
1.3. THE DEFINITION AND AETIOLOGY OF BACTERIAL VAGINOSIS  
BV is a clinical syndrome, previously known as non-specific vaginitis that is characterised by a 
disturbed vaginal ecosystem. The term “non-specific” was chosen to illustrate its poorly understood 
aetiology, diagnosis and treatment, and the term “vaginitis” used to describe infection of the vulva (Hill, 
1985). The identification of additional micro-flora involved and the recognition of a general absence of 
inflammation, resulted in the term “bacterial vaginosis” being adopted (Hay, 2002; Larsson & Forsum, 
2005; Filho et al., 2010; Sobel et al., 2012). Gardner & Dukes (1955) previously described the condition 
as having a characteristic discharge, increased vaginal pH and microscopically observed squamous 
vaginal epithelial cells with granular borders, which they named “clue cells” as they gave a clue to its 
diagnosis (Hill, 1985; Hay, 2002).  
 
BV manifests when the normally high lactobacilli concentrations in the vagina become reduced and are 
replaced by commensal Gram-negative and anaerobic micro-flora such as Gardnerella vaginalis, 
Mobiluncus species, Bacteroides species, Prevotella species, Mycoplasma species and more recently, 
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Atopobium vaginae (Schoonmaker et al., 1991; Spiegel, 1991; Kimberlin & Andrews, 1998; Hay, 2002; 
Goffinet et al., 2003; Ferris et al., 2004; Livengood, 2009; O’Hanlon et al., 2011). In addition to the 
organisms previously mentioned, Peptostreptococcus, Fusobacterium, Veilonella, Eubacterium species, 
Ureaplasma urealyticum and Streptococcus viridians may also be associated with BV (Tabrizi et al., 
2006). It has been demonstrated that a symbiotic relationship exists between G. vaginalis and 
Mycoplasma to promote the development of BV (Pybus & Onderdonk, 1999).  
 
While healthy individuals without BV have a more homogenous vaginal flora, a key characteristic of 
BV is its polymicrobial nature. BV-positive patients are rarely, if ever, colonised by a single organism or 
species (Fredericks & Marrazzo, 2005; Anukam & Reid, 2007). However, which of these organisms is 
essential for the proliferation and maintenance of BV, remains unclear (Hay, 2002). This review of the 
literature will focus predominantly on G. vaginalis and its association with BV and adverse pregnancy 
outcomes. 
 
1.4. EPIDEMIOLOGY OF BV AND ITS ASSOCIATION WITH ADVERSE PREGNANCY 
OUTCOMES 
BV is the most common cause of abnormal vaginal discharge affecting 5-51% of women of reproductive 
age (Schwebke, 2000; Hay, 2002; Bhalla et al., 2007; Koumans et al., 2007; Denny & Culhane, 2009; 
Verstraelen & Vershelst, 2009; Gillet et al., 2011; Sobel et al., 2012).  
 
There are specific factors that put women at risk of acquiring BV. These include age at first sexual 
intercourse, change in sexual partners, large number of lifetime sexual partners, coexisting STIs, menses 
and chronic stress (Gibbs, 2001; Marrazzo, 2011; Turovskiy et al., 2011).  
In addition, women who smoke are two times more likely to acquire BV than women who do not. 
Vaginal douching has also been associated with BV, by assisting in the ascent of lower genital tract 
organisms. This is a procedure followed by many Afro-Caribbean women, who are also classified as 
“high risk” for acquiring BV. However whether douching causes BV or whether the presence of BV 
results in a woman’s decision to douche, is unclear (Lliahi-Camp et al., 1996; U.S Preventive Services 
Task Force, 2008; Wang, 2000). In addition, women from African descent with low socioeconomic 
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status and previous PTD were found to be predisposed to acquiring BV in a subsequent pregnancy 
(Elyan and Rund, 2004). 
 
Sexual activity seems to be the most important risk factor, since BV is more commonly diagnosed in 
sexually active than inactive women (Madhivanan et al., 2008). Although BV is not considered to be a 
sexually transmitted disease (STD), it has been found in the male sexual partners of women with BV, 
suggesting it could be sexually associated (Lagacé-Wiens et al., 2008). But BV does not resemble a 
typical STD as multiple pathogens are involved, most of which normally occur in the vagina of healthy, 
sexually inactive women. However, more women are diagnosed with BV in STD clinics (33-64%) than 
prenatal or obstetric clinics (1.7-48.5%; Wang, 2000; Hay, 2005; Mullick et al., 2005; Turovskiy et al., 
2011). BV has also been diagnosed in 12-75% of asymptomatic women (Denny & Culhane, 2009: Sobel 
et al., 2012). 
 
BV has repeatedly been associated with adverse pregnancy outcomes, including PTD, late miscarriage, 
and premature rupture of membranes (PROM), infection of the chorion, amnion and amniotic fluid, and 
pelvic inflammatory disease (PID; Kimberlin & Andrews, 1998; Goffinet et al., 2003; US Preventive 
Services Task Force, 2008; Gondo et al., 2010; Marrazzo, 2011). Furthermore, BV has been detected in 
6.8-40% of women admitted for preterm labour at 23-37 weeks (Holst et al., 1994; Goffinet et al., 2003; 
Kumar et al., 2006). With the aid of Gram stain examination, BV was diagnosed in 11-87% of pregnant 
women between 23-26 weeks gestation (Hay et al., 1994; Hillier et al., 1995; Govender et al., 1996; 
Delaney et al., 2001; Goyal et al., 2005).  Because the condition may be asymptomatic, BV is diagnosed 
less frequently (15.8-17%) when using Amsel’s criteria (Goyal et al., 2005; Vogel et al., 2006). 
 
The mechanism by which BV-associated organisms cause preterm delivery is uncertain, but it has been 
linked to reduced leukocyte concentrations, elevated endotoxin levels and protease enzymes that 
stimulate proinflammatory cytokine and prostaglandin production leading to PTL, and possibly 
intrauterine death. The secretion of sialidase promotes placental inflammation and weakening of the 
chorioamniotic membrane, thereby causing lower genital tract organisms to ascend higher into the 
vagina. The inflammatory response induced by BV, presents paediatric problems as well. Cerebral palsy 
and bronchopulmonary dysplasia may develop as a result of increased levels of inflammatory cytokines 
in the amniotic fluid. Additionally, BV serves as a risk factor for long-term neurological complications, 
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such as hyperactivity and learning disabilities (Nelson et al., 2007; Denny & Culhane, 2009; Gondo et 
al., 2010; Turovskiy et al., 2011). 
 
BV diagnosed in the first 16 weeks of gestation increases the risk of both late miscarriage and PTD by 
1.8-7.3 times, independent of confounding factors. This suggests this is a critical period during gestation 
that allows BV-associated organisms to gain access to the upper genital tract, setting the stage for 
subsequent PTD (Kurki et al.; 1992; McGregor et al., 1993; Holst et al., 1994; Meis et al., 1995; 
Gratacós et al., 1998; Denny & Culhane, 2009). 
 
1.5. DIAGNOSTIC PROCEDURES FOR THE IDENTIFICATION OF BV 
BV is generally diagnosed by Gram stain examination using Spiegel or Nugent scoring (Spiegel et al., 
1983; Krohn et al., 1989; Nugent et al., 1991) and/or clinical symptoms (Amsel et al., 1983), often 
referred to as Amsel’s criteria. The identification and isolation of BV-associated organisms is often used 
as a screening tool for the diagnosis of BV, either by conventional methods or molecular techniques. 
Rapid diagnostic methods have also been developed to presumptively identify anaerobic vaginal flora 
commonly associated with BV, or their by-products. 
 
1.5.1 Amsel’s criteria 
In 1983, Amsel et al. proposed specific criteria for the clinical diagnosis of BV. The criteria involved the 
identification of three out of four clinical signs and/or symptoms including the identification of a grey, 
homogenous discharge, a pH greater than 4.5, amine odour in the presence of 10% potassium hydroxide 
(KOH) and the microscopic observation of clue cells of vaginal epithelial cells. A patient is BV positive 
if she tests positive for any three of the four criteria.  
Amsel’s criteria in its entirety is very useful in clinical settings as it does not rely on infrastructural or 
manual resources (Verstraelen & Verhelst, 2009; Modack et al., 2011).  However diagnosis of BV by 
this method is often erroneous.  An accurate diagnosis by Amsel’s criteria is dependent on clinical 
symptoms, but identification of these components is subjective (Chaijareenont et al., 2004; Donders, 
2007; Modack et al., 2011). 
 
1.5.1.1 Vaginal Discharge 
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A thin homogenous discharge may not always be indicative of BV, and in cases of asymptomatic BV 
in which there is no discharge present, the other three criteria could be analysed to make a diagnosis, 
but the presence of vaginal discharge has the lowest sensitivity and is non-specific (Verstraelen & 
Verhelst, 2009; Filho et al., 2010; Mittal et al., 2012). 
 
1.5.1.2 pH and amine production 
Vaginal pH >4.5 has good sensitivity for diagnosing BV. Detection of organic acids in vaginal 
secretions is useful for the presumptive identification of anaerobes in vaginal flora. Previously, gas 
liquid chromatography (GLC) was used to directly measure the characteristic organic acids in 
vaginal secretions produced by BV causing bacteria. GLC has since been replaced by electronic 
sensor array or the electronic nose to test for the presence of trimethylamine, considered to be 
responsible for the characteristic odour in BV. This can also be tested for with FemExam® test card 
which combines the detection of amine production with pH testing (Hill, 1985; Hay et al., 2003; 
West et al., 2003). Another rapid diagnostic method involves the self-test pH glove which allows 
women to monitor changes in vaginal pH by inserting a glove with a built-in pH indicator into the 
vagina and subsequently consult their doctor should they observe a pH of 4.7 or more,. This may 
enable prevention of adverse pregnancy sequelae (Hoyme & Saling, 2004). 
Considering the above, the possibility of acknowledging criteria individually or in pairs was 
investigated. Simoes et al. (2006) concluded that any of the Amsel criteria, either individually or in 
combinations of two, may be equally accurate as three, whereas Mittal et al. (2012) believe that 
using criteria such as pH and amine odour only are insufficient to diagnose BV.  
 
1.5.2 Microscopy 
Microscopic examination for the presence of “clue cells” (particularly if ≥20% of vaginal epithelial 
cells) is considered the most specific predictor of BV (Verstraelen & Verhelst, 2009; Filho et al., 2010; 
Mittal et al., 2012). 
 
As previously mentioned, microscopically, normal vaginal micro-flora consists largely of Lactobacillus 
morphotypes, while BV is characteristically dominated by G. vaginalis. This ignited the development of 
the Spiegel criteria for quantifying bacterial morphotypes in vaginal smears (Spiegel et al., 1983). 
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As a result of questionable inter-centre reliability of Spiegel criteria, Nugent et al. (1991) set out to 
develop a scoring system that uses morphotypes that are most reliably identified at different centres. 
Thus the Nugent score was proposed. Nugent scoring is a modification of the Spiegel criteria that 
produces a score of 0-10, thus enabling categorisation of the severity of BV. In this system, 
morphotypes were quantified as follows: 0 equals no morphotypes; 1+ equals ≤1 morphotype; 2+ equals 
1-4 morphotypes, 3+ equals 5-30 morphotypes and 4+ equals >30 morphotypes. This system is weighted 
such that the lack of lactobacilli yields the highest score.  As with the Spiegel criteria, lactobacilli and G. 
vaginalis are identified as large Gram-positive bacilli and small Gram-variable bacilli respectively. In 
addition, bacteria morphologically resembling Bacteroides species and Mobiluncus species are also 
identified. 
 
Several researchers have reported on the reliability and reproducibility of this method. It has consistently 
shown to be convenient, cost effective with high inter-observer and inter-centre reliability, and the scores 
obtained can give insight into the degree of alteration in vaginal micro-flora (Krohn et al., 1989; Nugent 
et al., 1991; Platz-Christensen et al., 1995; Chaijareenont et al., 2004; Zarakolu et al., 2004; Goyal et 
al., 2005; Money, 2005; Libman et al., 2006; Mohanty et al., 2010). Consequently, to maintain its 
accuracy, care should be taken when preparing and viewing the slides (Joesoef et al., 1991; Larsson et 
al., 2004; Mohanty et al., 2010). Whether or not it can be used as a screening tool, remains undecided 
(Krohn et al., 1989; Coppolilo et al., 2003). 
 
While the pathological condition of BV and normal micro-flora is easily defined, some abnormal vaginal 
micro-flora, such as intermediate flora, cannot be distinctly classified. Intermediate micro-flora are 
generally characterised by a mixed bacterial flora and is equivalent to a Nugent score of 4-6.  Therefore, 
there is some confusion as to what the intermediate micro-flora represents. It could either represent 
partial/intermediate BV, or more realistically, it could represent a transient state of BV, which could 
either regress to full-blown BV or progress to a healthy state (normal micro-flora). Furthermore, 
intermediate micro-flora has been strongly associated with various pregnancy complications, including 
mid-trimester pregnancy loss and PTD (Donders et al.; 2002; Donders, 2007; Lietich & Kiss, 2007). As 
a result, a new condition named Aerobic vaginitis (AV) has been described. AV is a condition 
characterised by the presence of facultative anearobic micro-organisms such as group-B streptococci and 
Escherichia coli. As with Nugent scoring, AV is diagnosed based on a composite score obtained by 
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noting the presence of leucocytes, parabasal cells and background flora. A score of 1 to 2 indicates 
normal or non-AV flora. A positive AV diagnosis is based on severity, where a score of 3 to 4 indicates 
slight AV, 5 to 6 indicates moderate AV and a score of greater than 6 is indicative of severe AV (Donders 
et al., 2002). This classification includes the immune reaction of the host and enables detailed and 
comprehensive division of micro-flora (Donders, 2007). 
 
1.5.3 Culture 
Culture techniques have long been the first approach in identifying the cause of infection. While culture 
for G. vaginalis has a high sensitivity for predicting a clinical diagnosis of BV, Gram staining vaginal 
smears are more specific. The sole purpose of utilising culture techniques in BV diagnostics would be to 
identify the organisms involved in the syndrome, but the presence of specific organisms, such as G. 
vaginalis, is not necessarily indicative of BV, as it is recovered in 50-60% of asymptomatic, healthy 
women. Additionally, several organisms associated with BV are difficult to cultivate, therefore their 
presence may be missed when using culture techniques (Delaney and Onderdonk, 2001; Kalra et al., 
2007; Verstraelen & Verhelst, 2009; Sobel et al., 2012), and thus, it is not recommended as a diagnostic 
tool for BV. 
 
Direct Fluorescent-Antibody developed by Hansen et al. (1987) is a simple, rapid test that enables 
detection of G. vaginalis in clinical samples from patients who have been treated with antibiotics and 
who test negative in culture. 
 
1.5.4 Enzyme Detection 
As previously stated, sialidases are important virulence factors of G. vaginalis. Sialidase activity can be 
tested for using BVBlue test which is a simple and rapid diagnostic chromogenic test for detecting BV 
by changing colour when sialidase activity is detected in vaginal fluid. It was found that 92% of women 
who tested positive for sialidase had signs of BV. This test would prove to be beneficial in the clinical 
setting where microscopic analysis is unavailable because it boasts good sensitivity and specificity when 
compared to Amsel’s criteria and Nugent scoring (Myziuk et al., 2003; Bradshaw et al., 2005; 
Numanović et al., 2008; Verstraelen & Verhelst, 2009). 
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1.5.5 Molecular biology 
Several molecular techniques and rapid diagnostic tests have been developed to aid in diagnosing BV. 
Since the study done by Burton & Reid (2002) that used Polymerase-chain reaction (PCR)-based 
techniques to characterise vaginal micro-flora, molecular diagnostic methods have become more popular 
and increased our understanding of the BV ecosystem and identified new species involved in the 
syndrome. 
The species-specific PCR (sPCR) is a universal technique used to detect a specific microorganism.  G. 
vaginalis is detected with 90% accuracy in BV-positive patients with the use of sPCR (Verhelst et al., 
2005). Alternatively, Quantitative real-time PCR (QRT-PCR) has excellent sensitivity and specificity, 
and can thus be used as a tool in diagnosing BV by detecting and quantifying Lactobacilli species, G. 
vaginalis and Mycoplasma hominis in the genital tract of women. With this method, G. vaginalis was 
detected significantly more frequently in women clinically diagnosed with BV while the converse 
occurred with Lactobacilli (Zarifard et al., 2002; Menard et al., 2008).  
 
Multiplex PCR-based methods differentiate BV from non-BV specimens by detecting several bacterial 
species that are associated with BV. The use of multiplex PCR is a more reliable indicator of BV than 
detection of a single bacterium, such as G. vaginalis (Obata-Yasuoka et al., 2002; Sha et al., 2005). 
Treating the PCR with proteinase K further enhances its sensitivity for detection of G. vaginalis. This 
test showed 100% correlation with the Nugent scoring system, and can accurately predict BV (Obata-
Yasuka et al., 2002). The advantage of PCR- based techniques is that it can be performed on samples 
directly, without prior culturing and allows identification of microorganisms with fastidious growth 
requirements. Its only requirement is that the nucleic acids should be intact. Conversely, it is limited by 
the possibility of false negatives and false positives. False negatives could result from PCR inhibitors 
present in clinical samples. Examples of PCR inhibitors are blood and mucus that may be present in 
vaginal secretions, consequently prior DNA extraction is recommended. False positives may occur when 
broad-range 16s rDNA PCR detect and amplify low concentrations of DNA found in laboratory 
reagents, DNA extraction kits, and PCR reagents (Fredericks & Marazzo, 2005; Menard et al., 2008); 
therefore very strict aseptic techniques should be applied.  
 
Several other PCR-based techniques can be used to detect vaginal pathogens, including cloning and 
denaturing gradient gel electrophoresis of the 16S rRNA gene or the chaperonin-60 gene, terminal 
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restriction fragment length polymorphism (RFLP) of the 16S rRNA gene and Fluorescence In Situ 
Hybridization (FISH). By detecting the presence of either A. vaginae or G. vaginalis, or both, 
amplification of the chaperonin-60 genesas demonstrated high specificity and sensitivity for the 
diagnosis of BV using microscopy as a gold standard (Verstraelen & Verhelst, 2009; Dumonceaux et al., 
2009; Lamont et al., 2011). 
BD diagnostics developed a DNA probe for G. vaginalis rRNA that only detects G. vaginalis at 
concentrations ≥2x105 CFU/ml. Although this test can be performed in an office setting, it produces 
better results in a laboratory, and shows promise in detecting G. vaginalis in pregnant women as a 
supplement to Amsel’s and Nugent criteria (Briselden & Hillier, 1994). 
 
It is evident that each diagnostic tool has its strengths and weaknesses. It is however essential to assess 
what needs to be achieved and which specific test will be used. Amsel’s criteria and point of care tests 
are more applicable for clinical settings, while PCR and chromatography can only be utilised in a 
laboratory. Gram staining appears to be more versatile because slides can be prepared in a clinic and 
safely transported to the laboratory for staining and analysis.  
 
1.6. TREATMENT OF BV 
The polymicrobial nature of BV makes it a difficult condition to treat (Joesof et al., 1999). BV usually 
occurs when hormonal changes lower vaginal pH, resulting in alteration of vaginal flora (Curran & 
Rivlin, 2012). Additionally, BV also has the ability to resolve spontaneously, and this phenomenon 
occurs in a third of non-pregnant women and half of pregnant women (Nelson & Macones, 2002; Sobel 
et al., 2012). Considering that the aetiology of the condition remains unexplained, managing it is 
difficult, resulting in high recurrence rates (Wilson, 2004; Harwich et al., 2010). Treatment of BV is 
aimed at resolving the symptoms and ensuring that follow-up screening is negative, thus it would not be 
beneficial to treat asymptomatic patients. Furthermore, treating asymptomatic women could result in 
symptomatic vaginal yeast infection. However, it is recommended to treat asymptomatic women 
scheduled for gynaecologic procedures prophylactically (Sobel et al., 2012).  
 
BV is generally treated by either systemic or topical Metronidazole or Clindamycin (Nelson and 
Macones, 2002). Bacteriotherapy could also be employed, which involves using non-toxic bacteria to 
dislodge pathogenic organisms (Wilson, 2004).  Clindamycin is a bacteriostatic antibiotic that targets 
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aerobes and Gram-positive and Gram-negative anaerobes, whereas Metronidazole is bactericidal and is 
usually successful in eliminating Gram-negative anaerobes.  Metronidazole does not act against 
Lactobacillus species; therefore the natural vaginal ecosystem is not markedly disturbed by the 
administration of this antibiotic.  
 
Modes of treatment for BV include 500mg oral Metronidazole, twice daily for seven days; 300mg oral 
Clindamycin twice daily for seven days and 0.75% Metronidazole vaginal gel once or twice a day for 
5days (Wang, 2000; Wilson, 2004; Hay, 2005). Alternative treatment options have been suggested, 
including 250mg oral Metronidazole, 5g Metronidazole intravaginally for 7 days (Curran & Rivlin, 
2012), 400mg Metronidazole for 5days (Hay, 2005) and 2% 5g Clindamycin vaginal cream either in a 
single dose or once daily for 5days (Livengood, 2009).  
 
All modes of treatment demonstrate significant cure rates. Orally administered Metronidazole 500mg 
twice daily for 7 days demonstrated cure rates of 23-99% whereas slightly lower cure rates of 26-81% 
were observed for 0.75% Metronidazole vaginal gel (Wang, 2000; Nelson & Macones, 2002; Wilson, 
2004; Yudin et al., 2008; Livengood, 2009; Harwich, 2010).  Although cure rates of 70-94% were 
demonstrated for oral Clindamycin 300mg twice daily for 7 days (Nelson & Macones, 2002; Yudin et 
al., 2008), the cure rate for topical Clindamycin is debatable. Livengood (2009) reported reduced cure 
rates (30-37%) for 2% Clindamycin vaginal cream, compared to a report by Wang (2000), indicating 
cure rates of 70-90% (Marrazzo, 2011). Despite the prosperity of treatment, 25-30% of women will 
experience recurrence within 1-3 months and 50% at 6-12 months. Recurrence could have two possible 
causes; 1) re-infection with a biotype different from the original infecting biotype, or 2) inadequate 
eradication of infecting organisms, and thus inability of normal protective lactobacilli to re-establish 
(Anukam et al., 2006; Numanović et al., 2008; Sobel et al., 2012). 
 
Since the first report on the use of yogurt to successfully treat BV during pregnancy (Neri et al., 1993), 
several researchers have tested the efficacy of Lactobacilliary probiotics for the treatment of BV 
(Shalev, 2002; Vitali et al., 2012). Probiotics are live strains of micro-organisms with beneficial effects 
on a patient’s health when administered in adequate amounts. Probiotics can be useful in the treatment 
of BV not only by replacing reduced lactobacilli concentrations but also by stimulating an 
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immunomodulation process. A 40% cure rate has been demonstrated in the use of probiotics to treat BV 
(Krauss-Silva et al., 2011; Othman, 2012).  
 
1.7. EVIDENCE FOR THE ROLE OF G. VAGINALIS IN THE PATHOGENESIS OF BV 
In order for micro-organisms to successfully colonise the host and avoid elimination by host defences, 
they require enzymes capable of penetrating the mucosal barrier. The pathogenesis of BV is complex 
and relatively unknown, but it is apparent that factors that enable invasion and colonisation of vaginal 
epithelia play an important role (Catlin, 1992; Diejamaoh et al., 1999). 
Biofilm production involves a group of bacteria adhering to the epithelial surface of a cell (Wilson, 
2001). Several studies have demonstrated the presence of a biofilm in patients with infections such as 
periodontal disease, endocarditis, foreign-body related infections, as well as BV. Biofilm formation has 
been shown to be an important virulence factor in BV, because its presence enables an increase in 
antibiotic and host immune defence resistance, as micro-organisms are able to become more 
concentrated than is possible in vaginal fluid (Hale et al., 2006). Primarily, BV was thought to be caused 
solely by G. vaginalis. Although G. vaginalis is isolated in 95% of cases of BV and encompasses 90% of 
the polymicrobial BV biofilm (Hale et al., 2006), it is also found in healthy women, and pure cultures of 
G. vaginalis do not cause BV, resulting in its pathogenic potential being questioned. However, it 
continues to play a pivotal role in development of BV (Turovskiy et al., 2011). 
 
In the initial stages in the pathogenesis of BV, G. vaginalis forms “clue cells”; this indicates its 
adherence ability. As a result of this ability, it is capable of forming a biofilm and is thus considered an 
initial coloniser. An initial coloniser is an organism that is able to adhere to the cell surface and 
subsequently enables the attachment of other micro-organisms with low innate pathogenic potential, to 
thrive in the vagina (Kalinka et al., 2004). G. vaginalis also produces sialidase and mucinase, which aids 
in attachment and invasion of the upper genital tract, and plays a role in bacterial nutrition, cellular 
interactions, immune response evasion and pathogenicity of bacteria (Briselden et al., 1992; Wiggins et 
al., 2001; Cauci et al., 2003; Bradshaw et al., 2005; Santiago et al., 2011). An additional, equally 
important, virulence factor of G. vaginalis is the production of a protein toxin, vaginolysin. Vaginolyin is 
a pore-forming toxin that disturbs the plasma membrane, subsequently causing cell lysis (Pleckaityte et 
al., 2011).  
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Cumulatively, the virulence properties of G. vaginalis enables adherence to vaginal epithelium, biofilm 
production and secretion of vaginolysin leading to cell lysis and tissue destruction.  The biofilm 
produced by G. vaginalis is extremely resistant to H2O2 and lactic acid (Patterson et al., 2010). This 
further enhances the proliferation and attachment of BV-associated organisms to the biofilm, even in the 
presence of lactobacilli (Udayalaxmi et al., 2011). This suggests that other BV-associated organisms take 
advantage of G. vaginalis’ powerful virulence properties and depend on G. vaginalis to prosper. 
Depending on growth conditions, G. vaginalis also produces synergistic or antagonistic compounds 
against lactobacilli and other vaginal bacterial compounds (Teixeira et al., 2010). It is been consistently 
illustrated that BV pathogens occur in various combinations, but always together with G. vaginalis, 
suggesting a symbiotic relationship exists between G. vaginalis and other BV pathogens (Pybus & 
Onderdonk, 1999; Menard et al., 2008). 
 
Biotyping and starch hydrolysis was initially introduced as a means of identifying and differentiating G. 
vaginalis from other coryneforms of vaginal origin (Piot et al., 1982). The technique was modified from 
tests used to identify Campylobacter fetus (Harvey, 1980) and Group B Streptococci (Hwang and 
Ederer, 1975), and was standardized and optimised according to G. vaginalis’ reaction. Generally, G. 
vaginalis can be characterised into specific biotypes based on biochemical reactions such as lipase and 
β-galactosidase activity, and hippurate hydrolysis (Numanović et al., 2008).  
 
Hippurate is a salt/ester of hippuric acid. Many bacterial species are able to hydrolyse hippurate and this 
ability is often tested to characterise and identify microorganisms (Kodaka et al., 1982). Hippurate is 
hydrolysed in a multi-step process, with the first by-product being benzoic acid. Initially hippurate 
hydrolysis was tested using ferric chloride as an indicator to detect benzoic acid. However, rapid tests 
have been developed to detect glycine, which is the second by-product, by using ninhydrine as an 
indicator to detect glycine production (Hwang and Ederer, 1975; Harvey, 1980; Luechtefeld and Wang, 
1982; Piot, 1982). Currently, there are several lipase assay methods that enable detection of lipase 
activity by making use of colorimetric or fluorescent substrates to be detected via spectrophotometry. A 
bacterium’s ability to synthesize and secrete lipase is influenced by environmental factors, such as ions, 
carbon sources and presence of non-metabolizable polysaccharides (Kurooka and Kitamura, 1978; 
Jeager et al., 1994). Lipases produced by bacteria hydrolyse esters of glycerol on a glycerol backbone of 
lipid substrates. This reaction takes place when hydrophobic lipid substrates are added to hydrophilic 
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aqueous solution. When there is a sudden increase in lipase activity and the substrate forms an emulsion, 
an interfacial area is created. This is called interfacial activation, which is characteristic of lipases. β-
Galactosidase is an enzyme that breaks down lactose into glucose and galactose, which are then used as 
carbon sources. It is coded for by lacZ gene in the lac operon of Escherichia coli. This is an example of 
a reporter gene, in which a virulence gene is fused with a structural gene. The synthetic chromogenic 
compound, o-nitrophenyl-β-D-galactoside (ONPG), is used as a substrate in place of lactose. When 
ONPG is cleaved, galactose and o-nitrophenol is produced. While ONPG is colourless, o-nitrophenol 
has a yellow colour. The rate of production of o-nitrophenol is proportional to the concentration of β-
galactosidase. Therefore, the production of yellow colour can be used to determine β-galactosidase 
concentration (Miller, 1972; Salyers and Whitt, 1994).  
 
Currently, two biotyping schemes exist. The scheme by Piot et al. (1984) recognises eight biotypes, 
while Benito et al. (1986) identified seventeen. The distribution of biotypes of G. vaginalis differs 
among geographical regions (Piot et al., 1984). Piot et al. found that while biotypes 1, 2 and 5 were 
more frequently isolated in Seattle, USA and Antwerp, Belgium, biotypes 1 and 5 are most common in 
Nairobi, Kenya. In another study testing subjects from Seattle, biotypes 1, 5 and 6 were found to be most 
common (Briselden and Hillier, 1990). In Bosnia, Numanvovic et al. (2008) found biotypes 2, 3, and 7 
occurred most frequently.  
 
Certain biotypes have also been associated with BV. While Piot et al. found no particular biotype 
associated with BV, other studies found biotypes 1, 2, 3, 4, 5 and 7 to be associated with BV. Biotypes 
1, 2, 4, 5 and 7 are most prevalent in women presenting with clinical symptoms of BV (Benito et al., 
1986; Ison et al., 1987; Scott et al., 1987). The male sexual partner of women diagnosed with BV 
harboured the same biotypes, supporting the notion that G. vaginalis is sexually transmitted. However, 
this does not mean that BV is a STD; instead G. vaginalis is a pre-cursor for the development of BV 
(Numanvović et al., 2008).  
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1.8. SUMMARY AND OBJECTIVES 
Bacterial vaginosis (BV) is characterised by reduced Lactobacilli species concentration and an 
overpopulation of Gram-negative anaerobic bacteria, including Gardnerella vaginalis, Mobiluncus, 
Bacteriodes, Atopobium vaginae, Prevotella and Mycoplasma species. BV is a polymicrobial and very 
complex vaginal syndrome, the aetiology of which is relatively unknown. It affects 50-80% of the 
female population of reproductive age.  
 
G. vaginalis seems to play an important role in the development of BV, as several of its virulence factors 
are required to allow attachment of other BV-associated pathogens and the production of BV symptoms. 
Additionally, a symbiotic relationship has been observed between G. vaginalis and several other 
organisms involved in BV, suggesting a significant role for G. vaginalis in the establishment of the BV 
biofilm and therefore, for preterm birth. 
 
 Null hypothesis (H0) 
Ho: G. vaginalis is not associated with BV in mothers with a history of preterm birth. 
 
The aim of this study is to establish the prevalence of G. vaginalis in pregnant women with a history of 
preterm delivery. 
 
The objectives are: 
 To investigate maternal risk factors for previous pregnancy outcome and BV 
 To examine for the prevalence of G. vaginalis in BV patients 
 To determine the accuracy of culture and microscopy for detecting G. vaginalis in BV 
 To characterise the G. vaginalis isolates for their biotypes and antibiograms 
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Chapter 2: Materials and methods 
 
2.1.  SUBJECT SELECTION 
A total of 301 pregnant women receiving antenatal care at four Midwife and Obstetrics Units, including 
Mowbray, Khayelitsha, Mitchell’s Plain and Gugulethu were selected to participate in this study. Of 
these, 150 had a history of full-term delivery (FTD) with no pre-term delivery and 151 had a history of 
preterm delivery (PTD). Women were enrolled in the study on their first prenatal visit. Informed consent 
was obtained by means of a consent form after they received detailed information regarding the nature 
of the study and sampling methods to be used. The research assistant at the clinic completed a short 
questionnaire outlining demography, medical history and social behaviour, and for purposes of 
anonymity, patients were identified by a sample number, which was recorded along with their folder 
numbers (Appendix A). Where necessary, an interpreter was employed. Specific inclusion criteria were 
implemented for enrolment in the study. For the pre-term delivery group (PTDG), subjects were selected 
based on the following inclusion and exclusion criteria: pregnant woman at ≥28weeks gestation with a 
history of at least one previous spontaneous pre-term delivery (between 24 and 37weeks gestation). For 
the full-term delivery group (FTDG) selection was determined by the patient having at least one 
previous, uncomplicated spontaneous term delivery (after 37weeks gestation) with no pre-term delivery. 
Patients not falling within the above-mentioned gestational period and patients, who had received 
antibiotic therapy three weeks prior to being examined, were excluded from the study.  
Ninety (29.90%) samples were collected from Mowbray Maternity hospital (MMH), 74 (24.58%) from 
Khayelitsha MOU (KMOU), 86 (28.57%) from Mitchell’s Plain MOU (MPP) and 51 (16.94%) from 
Gugulethu MOU (GUG).  
 
2.2. SAMPLE COLLECTION 
Vaginal samples were collected without a speculum using sterile cotton swabs and immediately 
transferred to Amies transport media with charcoal (18114CST, Sterilin) and transported to the 
laboratory.  
Amsel criteria were not used for diagnostic purposes since the aim of the study was to test the accuracy 
of the use of microscopy and culture only for the detection of BV and G. vaginalis.  
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2.3. LABORATORY/MICROSCOPICAL EXAMINATION  
Vaginal smears were prepared from the swab for microscopic examination. The smears were allowed to 
air-dry before being heat-fixed and Gram stained by Koppeloff’s modification using safranin as counter 
stain. Using the Nugent scoring system of bacterial morphotypes (Nugent et al., 1991), the presence or 
absence of BV was recorded.   
 
In conjunction with Nugent scoring, slides were also examined for clue cells. An epithelial cell was 
considered a clue cell if the borders of the cell were completely surrounded with bacteria and had edges 
that look “grainy”. If any part of the border of the cell was clear, it was not considered a clue cell. More 
importantly, a sample was only positively diagnosed with clue cells if there were ≥20% clue cells per 
field. 
 
2.3.1. Nugent Score 
The Nugent score is a scoring system from 0-10, which enables gradation of the severity of BV. The 
scoring criterion computes a weighted quantification to yield a score of 0 – 10.  At least four 
microscopic fields were examined for approximately two minutes per field. A Nugent score was 
allocated based on the average of the four fields examined.  
Three morphotypes (Lactobacillus, Bacteroides/Gardnerella & Mobiluncus spp.) were quantitated on a 
scale of 1 to 4 as follows: 1+ (< 1 cell per field), 2+ (1 to 5 cells per field), 3+ (6 to 30 cells per field) 
and 4+ (> 30 cells per field). The total scores were then computed by adding the weighted quantitation 
(0 to 4+) of the three morphotypes to yield a score of 0-10. A score of 1-3 was representative of a 
vaginal ecosystem dominated by Lactobacillus species and was thus categorised as normal flora. A 
score of score 7-10 was allocated when lactobacilli were severely reduced and replaced with 
Gardnerella/Bacteriodes-like morphotypes, thus indicatingbacterial vaginosis. Where a score of 4-6 was 
allocated, indicating intermediate flora, a mixed vaginal ecosystem was observed, whereby both 
Lactobacillus and Gardnerella/Bacteriodes-like morphotypes were present (Table 1).  
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Table 1: Scoring vaginal Gram stains for Bacterial Vaginosis (Nugent et al., 1991) 
Morphotypes Number per oil immersion field Score
Lactobacillus-like (parallel-sided, 
Gram-positive rods) 
> 30 
5-30 
1-4 
<1 
0 
1 
2 
3 
Gardnerella/Bacteriodes-like (tiny, 
Gram-variable coccobacilli and 
rounded, pleomorphic, Gram-negative 
rods) 
<1 
1-4 
5-30 
>30 
1 
2 
3 
4 
Curved Gram-variable rods 
0 
1-2 
3-4 
0 
1 
2 
 
2.3.2. Aerobic vaginitis 
Gram stained slides were examined to classify cases of intermediate flora as possible aerobic 
vaginitis (AV), as described by Donders et al. (2002). Briefly, Lactobacillary grades formed the 
basis of a combined score (Table 2). Lactobacillary grades (LBG) are defined as follows: I = 
numerous pleomorphic lactobacilli, no other bacteria; IIa = mixed flora, but predominantly 
lactobacilli; IIb = mixed flora, but proportion of lactobacilli severely decreased due to increased 
number of other bacteria: III = lactobacilli severely depressed or absent because of overgrowth of 
other bacteria. One or more of the following were added to the above LBG: leucocytes, presence of 
toxic leucocytes, presence of parabasal cells (PBCs), no PBCs: score = 0; PBCs representing <10% 
of epithelial cells: score = 1; PBCs >10%: score = 2 and background flora. For background flora, a 
score = 0 indicated unremarkable flora, or debris and bare nuclei from lysed epithelial cells; score = 
1 indicated course or small bacilli resembling lactobacilli morphotypes; score = 2 indicated 
prominent or chained cocci. A composite score of 1-2 signifies normality, while a score of 3-4 
indicates slight AV and score of 5-6 corresponded to moderate AV. A score of greater than 6 (but 
not more than 10) represented severe AV (Table 2). 
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Table 2: Criteria for the microscopic diagnosis of aerobic vaginitis  
AV 
Score 
LBG No. of leukocytes 
Proportion of toxic 
leukocytes 
Background flora 
Proportion of 
PBC 
0 
I and 
IIa 
≤10/ hpf None or sporadic Unremarkable or 
cytolysis 
None or < 1% 
1 IIb 
>10/hpf and ≤ 10/epithelial 
cell 
≤ 50% of leukocytes Small coliform bacilli ≤ 10% 
2 III > 10/epithelial cell > 50% of leukocytes Cocci or chains >10% 
Hpf: high power field (100 × magnification).  
 
2.4. CULTURE 
Samples were cultured on Columbia blood agar base (CM0331B, Oxoid) containing G. vaginalis 
selective supplements (SR0119E, Oxoid) and 5% sheep blood and streaked for single colonies. Cultures 
were incubated in an anaerobic jar containing gas-generating kit (BR0038B, Oxoid) at 370C for 48hours. 
After incubation, cultures were examined for small, grey, opaque -haemolytic colonies.  Smears were 
made for Gram staining to confirm the presence of G. vaginalis. The presence of small Gram-variable 
pleomorphic bacilli was considered to be indicative of G. vaginalis. 
 
Samples were stored in Prolab Microbank cryovials (PL170M, Davies Diagnostics) at -800C for all 
subsequent tests. 
 
2.5. ANTIBIOTIC SENSITIVITY TESTS 
Antibiotic sensitivity tests were performed on all isolates of G. vaginalis.  Isolates were sub-cultured on 
G. vaginalis selective agar and incubated anaerobically, to ensure purity of cultures. A bacterial 
suspension was created in 5ml Todd Hewitt Broth (CM0189, Oxoid) to a concentration of 6-9 x 108 
colony-forming units (CFUs) per millilitre. Tubes were briefly vortexed, after which 100µl of broth 
suspension was inoculated onto each plate. The test was done in duplicate for accuracy. The inoculum 
was then evenly spread over the plate surface using a sterile glass spreader. Plates were allowed to dry 
very briefly before placing antibiotic discs, 100µg Sulphonamide, 50µg Metronidazole and 10µg 
Clindamycin (DD0011, DD0008 and CT0015, Oxoid), in three corners of the plate. Culture plates were 
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incubated anaerobically at 370C and examined at 24 and 48 hour intervals to observe sensitivity or 
resistance. If sensitivity was observed, the diameter of the zone of inhibition was measured using a ruler. 
Zone diameter size was measured as the distance from the antibiotic disc to the edge of the area of 
bacterial growth and interpreted as per manufacturer’s instructions as follows: 
Clindamycin: resistant = ≤14mm; sensitive = ≥21mm 
Metronidazole: resistant = ≤10mm; sensitive = ≥10mm   
 
2.6. G. VAGINALIS BIOTYPING 
Several biochemical tests were performed to characterise G. vaginalis into 8 biotypes (Piot et al., 1982). 
All samples were sub-cultured prior to testing to ensure samples were viable and pure.   
 
2.6.1. Lipase activity assay 
Lipase activity was measured using QuantiChromTM Lipase assay kit (BioAssay Systems, DLPS-100). It 
is a rapid colorimetric determination of lipase activity at 412nm. The assay was performed as per 
manufacturer’s instructions.  
 
Working agent was prepared by mixing colour reagent with assay buffer, and then adding the 
dimercaptopropanol tributyrate (BALB) reagent. As this assay is based on a kinetic reaction, addition of 
the working reagent should be swift.  
Samples were dispersed in phosphate buffered saline and centrifugation at 14,000rpm for 5min. In a 96 
well microtitre plate, 150μl sterile distilled water was added to the first well and 150μl calibrator was 
added to the second well. Ten microliters of sample was added to subsequent wells, after which 140μl 
working reagent was added. A spectrophotometry reading of the plate was taken at OD412nm on a plate 
reader (Anthos 2010) after 10min (OD10min) and 20min (OD20min) incubation periods at room 
temperature. Lipase activity was calculated using the formula below: 
 
 Activity = OD20min – OD10min              x 735 (U/L) 
             ODCalibrator – ODH2O 
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where OD20min and OD10min are the OD412nm values of the sample at 20 min and 10 min, respectively. 
ODCalibrator and ODH2O are the OD412nm values of the Calibrator and water at 20 min. The number “735” 
is the equivalent activity (U/L) of the calibrator under the assay conditions. 
 
2.6.2. β-Galactosidase activity  
A substrate solution was prepared, consisting of 0.4% 2-nitrophenyl-β-D-galactopyronoside (48712-
1GM, Merck & Co), 75ml sterile distilled water and  25ml buffer solution (NaH2PO4.1H20 + 40ml dH20 
(pH7) ). The substrate solution was dispensed in 1ml microtubes in 0.5ml aliquots. Microtubes were 
inoculated with a loopful (~10μl) of 24hour culture of G. vaginalis and incubated at 370C in a water bath 
for 4hours and 18hours. Tubes were examined after every incubation period for the appearance of a 
yellow colour (Piot et al., 1984) 
 
2.6.3. Hippurate Hydrolysis assay 
A rapid hippurate test kit (Hardy Diagnostics, Z52) was used to determine the ability of G, vaginalis 
isolates to hydrolyse the compound hippurate. The test was performed as per manufacturer’s 
instructions. Briefly, a hippurate test tube containing 20mg Sodium Hippurate was dissolved by adding 
3-4 drops (~0.2ml) distilled water to the tube. The tube was then heavily inoculated with cultures using a 
sterile inoculating loop. Tubes were then incubated for 2 hours at 35-37oC. Meanwhile, the Ninhydrin 
indicator solution was reconstituted in 2ml distilled water. The solution was mixed by shaking the 
dropper bottle vigorously, and allowed to dissolve at room temperature until tubes were removed from 
the incubator. Following the incubation period, 2 drops of Ninhydrin indicator solution was added to the 
hippurate-sample mixture. Tubes were subsequently re-incubated at 35-37oC and observed at 10 minute 
intervals for 30min for a deep blue/purple colour change, indicating a positive test.   
 
Following completion of the above tests, samples were categorised according the scheme tabulated in 
Table 3.  
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Table 3: Biotypes of G.vaginalis 
Biotype number 
Feature 1 2 3 4 5 6 7 8 
B-Galactosidase + - - + - + - + 
Lipase + + + + - - - - 
Hippurate Hydrolysis + + - - + + - - 
Piot et al., 1984 
 
2.7. STATISTICAL ANALYSIS 
Statistical analyses were carried out using SPSS 17.0 (SPSS Inc., Chicago, IL).  Categorical data were 
analysed using the chi-square test. Where an expected cell value was greater than 20%, Fisher’s exact 
test was used. Non-parametric data was analysed using the Mann-Whitney U-test. A p-value of 0.05 was 
considered as significant. Logistic regression was used to determine significant correlations. 
 
The accuracy of the diagnostic tests (microscopy and culture) was expressed by using the following 
formula: 
Sensitivity: TP/ (TP+ FN), Specificity: TN/ (FP + TN), positive predictive value (PPV): TP/ (TP + FP), 
negative predictive value (NPV): TN/ (FN + TN), Positive odds ratios: Sensitivity/1 – specificity while 
negative odds ratios were obtained by the following formula: FN/TP + FN divided by TN/FP +TN. The 
percentage accuracy for each method was calculated using the formula: TP + TN/sample number X 100. 
TP: True positive, TN: true negative, FN: false negative, FP: false positive. 
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 Chapter 3: Results 
 
3.1. DEMOGRAPHICS 
Three-hundred and one women with a history of either pre-term (PT) or full-term (FT) delivery 
participated in this study. Prior to swab sample collection, participants were asked to complete a 
questionnaire in order to identify factors which might pose a health risk. The responses to the 
questionnaire are summarized in Table 4 and Table 5. Logistic regression analysis demonstrated a good 
model of fit and 35% of the independent variables reflected in this study explained the variance in pre-
term delivery group (PTDG). The variables STI, HIV, clinical symptoms and douching had to be 
extracted from the model as collectively, they had too many missing data. Except for location and 
smoking, none of the variables had a significant effect on pregnancy outcomes.  
 
3.1.1. Location of population groups 
The four locations from which samples were collected serve a mainly under-privileged, black and 
coloured community. Most of the study patients attended Mowbray (MMH; 29.9%), and a statistically 
significant association between location and pregnancy outcomes was observed (p = 0.000). The women 
attending Gugulethu (GUG) and Khayelitsha (KMOU) Maternity units are predominantly black, while 
MMH and Mitchell’s Plain (MPP) serve both black and coloured patients. Women from GUG were 
found to have a 14 times greater chance of having a history of PTD than those from MMH (Table 4). 
 
3.1.1. Age 
The age of the study population ranged from 19-42 years with an average age of 28 years. In PTDG and 
full-term delivery group (FTDG), most of the study patients were in the 26-30 year age range viz. 52 
(34.4 %) for PTDG and 54 (36%) for FTDG (Table 4). Forty-four (29.1 %) of PTDG were in the age 
range of 19-25 years, while 36 (24%) of FTDG were in this range. The lowest percentage of women 
participating were in the ≥41year age range, 2 (1.3%) in PTDG and 6 (4%) in FTDG. There was no 
statistically significant association between age of subject and history of pregnancy outcomes.  
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Table 4: Summary of population demographics 
Characteristic Frequency n (%)  
 PTDG 
n=151 
FTDG 
n=150 
Total 
n=301 
Significance 
levels 
Locations a 
 MMH 
 KMOU 
 MMP 
 GUG 
 
56 (37.1) 
26 (17.2) 
34 (22.5) 
35 (23.2) 
 
34 (22.7) 
48 (32.0) 
52 (34.7) 
16 (10.7) 
 
90 (29.9) 
74 (24.6) 
86 ( 28.6) 
51 (16.9) 
 
 
p = 0.000 
Age Distribution 
 19-25 Years 
 26-30 Years 
 31-35 Years 
 36-40 Years 
 ≥ 41 Years 
 
44 (29.1) 
52 ( 34.4) 
34 (22.5) 
14 (9.3) 
2 (1.3) 
 
36 (24.0) 
54 (36.0) 
38 (25.3) 
13 (10.7) 
6 (4.0) 
 
80 (26.6) 
106 (35.2) 
72 (23.9) 
27 (9.0) 
8 (2.7) 
 
 
 
p = 0.730 
Marital Status 
 Single 
 Married 
 Boyfriend 
 
72 (47.7) 
70 (46.4) 
8  (5.3) 
 
73 (48.7) 
64 (42.7) 
6 (4.0) 
 
145 (48.2) 
134 (44.5) 
14 (4.7) 
 
 
p = 0.846 
Gravidity 
 0-3 
 4-5 
 ≥7 
 
118 (78.1) 
31 (20.5) 
2 (1.3) 
 
128 (85.3) 
22 (14.7) 
0 (0.0) 
 
246 (81.7) 
53 (17.6) 
2 (0.7) 
 
 
p = 0.695 
Parity 
 0-3 
 4-5 
 ≥7 
 
146 (96.7) 
5 (3.3) 
0 (0.0) 
 
144 (96.0) 
6 (4.0) 
0 (0.0) 
 
290 (96.3) 
11 (3.7) 
0 (0.0) 
 
 
p = 0.003 
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Level of Education  
 Primary school 
 Secondary school 
 Tertiary/University 
 
6 (4.0) 
138 (91.4) 
5 (3.3) 
 
8 (5.3) 
135 (90.0) 
5 (3.3) 
 
14 (4.7) 
273 (90.7) 
10 (3.3) 
 
 
p = 0.681 
Employment 
 Yes 
 No  
 Unknown 
 
59 (39.1) 
91 (60.3) 
1 (0.66) 
 
59 (39.3) 
89 (59.3) 
2 (1.3) 
 
118 (39.2) 
180 (59.8) 
3 (0.9) 
 
 
p = 1.000 
a: MMH, Mowbray MOU; KMOU, Khayelitsha MOU; MMP, Mitchell’s Plain MOU; GUG Gugulethu MOU 
 
3.1.2. Marital Status 
While there was no statistically significant difference (p = 0.846) between marital status across the two 
groups (PTDG and FTDG), it should be noted that the number of single and married women only 
differed by a small margin, 145 (48.2%) and 134 (44.5%) respectively (Table 4). 
 
3.1.3. Parity & Gravidity 
The total number of previous pregnancies averaged at 2.75 (±1.10) For PTDG, it ranged between 1 and 
7 with an average of 2.78 (±1.22), while for FTDG the range was between 2 and 6 with an average of 
2.65 (± 0.96). In both PTDG and FTDG, majority of the women had 0-3 previous pregnancies (78.1% 
and 85.3% respectively). Similarly, a parity of 0-3 was most prevalent in both FTDG and PTDG. While 
a statistically significant difference of average parity was demonstrated (p = 0.003), none was detected 
with gravidity across PTDG and FTDG (Table 4).  
 
3.1.4. Education 
All participants obtained some level of education (Table 4). A large percentage (90.7%) reached 
secondary school, 138 (91.4%) of which were in PTDG and 135 (90%) in FTDG, but only 62 (41.1%) 
and 55 (36.4%) respectively completed secondary school. From each group, 5 (3.3%) received tertiary 
education. 
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3.1.5. Employment  
More than half of the study population was unemployed and an enough an equal number (59, 39.1% and 
39.6% respectively) of patients from both groups were employed. However, those who were employed 
held low income occupations such as municipal workers, cashiers or domestic workers (Table 4). 
 
3.2. HEALTH ASSESSMENT 
 
3.2.1. Smoking & Alcohol consumption 
A statistically significant relationship was observed between smoking (p = 0.020) but not alcohol 
consumption (p = 0.413) and a history of PTD. There were more smokers among PTDG (18.54%) than 
among FTDG (8.61%; Table 5). However, the majority were non-smokers. Similar results were seen 
with alcohol consumption. Twelve of 151 (7.95%) patients in PTDG consumed alcohol, while 139 
(92.05) did not. Likewise, 17 of 150 (11.26%) of FTDG consumed alcohol and 132 (87.42%) did not. 
Logistic regression revealed non-smokers were 83% less likely to have a history of PTDG. 
 
3.2.2. History of STI 
Overall, a larger percentage (72.43%) of the study group had not been previously diagnosed with a 
sexually transmitted infection (STI; Table 5). Although 21.19% of PTDG were previously diagnosed 
with an STI compared with 12.67% of FTDG, this difference was not statistically significant (p = 
0.350). 
 
3.2.3. HIV status 
Although not all patients disclosed their HIV status, 25.83% of PTDG and 23.18% of FTDG were HIV-
positive (Table 5), and 7.5% PTDG and 10.6% FTDG had not been previously tested for HIV.  Of the 
study population, 66.23% of the PTDG and 65.56% of the FTDG were HIV-negative. 
 
3.2.1. Clinical symptoms 
Clinical symptoms which were apparent upon sample collection included urinary tract infections and 
vaginal discharge. In PTDG, only 3.02% and12.67% of FTDG presented with urinary symptoms (Table 
5). Although, there were more women with no clinical symptoms in PTDG (40.40%) than FTDG 
(9.33%), vaginal discharge was more common in FTDG (78%) than in PTDG (59.95%). 
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Table 5: Summary of Health assessment information obtained from questionnaire 
Characteristic Frequency (%) 
 PTDG
n=151
FTDG
n=150
Total 
n=301 
Significance 
level 
Cigarette Smoking 
 Yes 
 No 
 
28 (18.54) 
123 (81.46) 
 
13 (8.61) 
137 (91.33) 
 
41( 13.62) 
260 (86.38) 
 
p = 0.020 
 
Alcohol consumption 
 Yes 
 No 
 Unknown 
 
12 (7.95) 
139 (92.05) 
 
17 (11.26) 
132 (87.42) 
1 (0.33) 
 
29 (9.63) 
271 (90) 
1 (0.33) 
 
 
p = 0.413 
STI 
 Yes 
 No 
 Unknown 
 
32 (21.19) 
102 (67.55) 
17 (11.26) 
 
19 (12.67) 
116 (77.33) 
15 (10) 
 
51 (16.95) 
218 (72.43) 
32 (10.63) 
 
 
p = 0.350 
HIV 
 Negative 
 Positive 
 Unknown/non 
reactive 
 
100 (66.23) 
39 (25.83) 
12 (7.95) 
 
99 (65.56) 
35 (23.18) 
16 (10.60) 
 
199 (66.11) 
74 (24.58) 
28 (9.30) 
 
 
p = 0.982 
Clinical  Symptoms 
 Vaginal 
discharge 
 Urinary 
symptoms 
 None 
 
86 (59.95) 
 
2 (3.02) 
 
61 (40.40) 
 
117 (78) 
 
19 (12.67) 
 
14 (9.33) 
 
176 (58.47) 
 
21 (6.98) 
 
59 (19.60) 
 
 
 
p = 0.009 
 
Personal Hygiene 
Bathing option 
 Bath 
 Shower 
 Hand wash 
Douching 
 Yes 
 No 
 Unknown 
 
 
39 (25.83) 
12 (7.95) 
100 (66.23) 
 
0 (0) 
39 (25.83) 
69 (45.70) 
 
 
32 (21.33) 
7 (4.67) 
107 (71.33) 
 
1 (0.67) 
44 (29.33) 
105 (70) 
 
 
71 (23.59) 
19 (6.31) 
207 (68.77) 
 
1 (0.33) 
83 (27.57) 
174 (57.81) 
 
 
 
 
p = 0.265 
 
 
 
p = 1.000 
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3.2.1. Personal hygiene practices 
As a result of poor living conditions, most of the women involved in this study (207, 68.77%), had to 
resort to washing in a basin as a bathing option. A smaller number of patients kept clean by showering, 
i.e. 7.95% of PTDG and 4.67% of FTDG, while the rest, 25.83% and 21.33% respectively, chose to bath 
(Table 5).  
Only one person, from FTDG, practiced douching, while 175 women did not respond to that question 
for reasons which remain unknown. There was no statistically significant relationship between the 
PTDG and FTDG for personal hygiene practices and a previous PTD (Table 9).  
 
Figure 1: Photographic representation of Gram stain of vaginal smears from (A) a patient 
harbouring high number of Lactobacilli ssp.(a) indicative of NF, (B)  clue cell, the borders of 
which are obscured by bacteria,  a characteristic feature of BV and (C) a patient with high levels 
of curved Gram negative rods (c) and Gram-variable rods (d) indicating BV. 
a 
B C
a 
c
b 
d 
A 
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3.3. PREVALENCE OF BACTERIAL VAGINOSIS ASSESSED MICROSCOPICALLY 
 
3.3.1 Microscopic evaluation 
The Amsel’s criteria are generally used to make a diagnosis of BV within a clinical setting. The 
presence of clue cells is probably the most important criterion and can be detected microscopically 
either by saline wet mount or, less often, by Gram-staining. However, the clinics at which samples were 
collected are severely understaffed and can get quite busy. As a result, only vaginal swab samples could 
be collected, and therefore all clinical criteria to diagnose BV could not be applied. However, we used 
this limitation to establish the accuracy of microscopy and culture to detect BV in mothers associated 
with previous PTD.  
 
Vaginal swabs were smeared on a glass slide and Gram-stained using safrinin as counterstain. Slides 
were analysed and scored according to Nugent scoring criteria (Nugent et al., 1991) as described in 
Chapter 2 (Materials & Methods). Briefly, bacterial morphotypes with a score of 0-3 represents high 
numbers of Lactobacilli spp., indicative of normal vaginal micro-flora, while a score of 4-6 indicates 
intermediate flora and a score of 7-10 represents high numbers of Gram-negative to Gram-variable rods 
and absence of lactobacilli, which is indicative of bacterial vaginosis.  Gram-stained slides were 
examined for the presence of clue cells, which are epithelial cells whose borders are completely 
surrounded by bacteria. More importantly, a sample was only positively diagnosed with clue cells if 
there were ≥20% clue cells per high-power field (Figure 1). 
 
In PTDG, a total of 151 slides were examined, while 150 slides were examined in FTDG. Gram stain 
analysis of vaginal swabs revealed that 96 of 301 (32%) of the study population harboured vaginal flora 
indicative of BV, 47 of which were in PTDG and 49 were in FTDG (Table 6).  
 
While no statistically significant association (p = 0.618) was observed between a history of PTD and the 
presence of clue cells, clue cells were more frequently detected in PTDG (13.9%) women than women 
from FTDG (11.3%; Table 6), particularly in patients with a positive BV diagnosis, demonstrating a 
statistically significant association between BV and clue cells (p = 0.000). The majority of the 
population had a score indicative of normal micro-flora, with similar numbers being observed in PTDG 
(52.3%) and FTDG (52%). A small group of women presented with intermediate flora. Intermediate 
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flora was observed in 16.6% of PTDG while 14.7% of FTDG had intermediate flora (Table 6). No 
statistically significant association was found between a history of PTD and a positive diagnosis of BV 
(p = 0.893).	
 
With the application of reclassification of intermediate flora to Aerobic vaginitis (AV; Donders et al.et 
al.., 2002) AV was diagnosed in 42 (27.8%) of PTDG and 37 (24.7%) of FTDG subjects (Table 6). 
Twenty-eight of the 47 (59.6%) subjects previously classified as intermediate was reclassified as AV, of 
which 13 (27.7%) were from PTDG and 15 (31.9%) from FTDG.  
	
Table 6: Microscopy 
NF: Normal flora; IF: intermediate flora; BV: Bacterial vaginosis; AV: Aerobic vaginitis 
 
 
3.4.   PREVALENCE OF GARDNERELLA VAGINALIS 
 
3.4.1.  Isolation 
The presence of G. vaginalis was determined by culture and confirmed by Gram staining (Table 7). G. 
vaginalis was detected in 144 (47.8%) of the 301 (95% confidence interval (CI) 0.42-0.54) women 
studied of which 78 (51.7%; CI 0.42-0.54) had a previous PTD and 66 (44%; 95% CI 1.191-2.001) had 
a previous FTD, with no significant relationship (p = 0.225) between the isolation of G. vaginalis and a 
previous PTD being observed (Figure 2). 
 
 
 PTDG n=151 (%) FTDG n=150 (%) Significance levels 
NF 79 (52.3) 78 (52.0)  
IF 25 (16.56) 22 (14.7)  
BV 47 (31.1) 49 (32.7) 0.893 
Clue cells 21 (13.9) 17 (11.3) 0.618 
AV 42 (27.8) 37 (24.7) 0.649 
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Figure 2: Graphical presentation indicating the percentage of women who harboured Gardnerella 
vaginalis in both PTDG and FTDG 
 
3.4.2. Antibiograms 
Clinical isolates of G. vaginalis were tested for their susceptibility to antibiotics generally used to treat 
BV (Table 7). The sample numbers for PTDG and FTDG were reduced to 73 and 60 respectively as a 
result of plate contamination and subsequent loss of samples. Antimicrobial activity towards 
Clindamycin was similar between the two groups. Clindamycin exhibited antimicrobial activity towards 
75.3% of PTDG and 76.7% of FTDG isolates. Antimicrobial patterns remained constant over the 48 
hour incubation period (Table 7).  
 
As indicated in Figure 3 and Figure 4, all G. vaginalis isolates in PTDG were resistant to Metronidazole, 
and with the exception of 1 (1.7%) isolate from FTDG, so were the isolates from FTDG.  Sulphonamide 
was used as a reference as G. vaginalis is known to be resistant to its action. 
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Table 7: Prevalence of G. vaginalis 
 
Isolation 
Susceptible strains  
Metronidazole Clindamycin 
PTDG  51.7% 0.0% 75.3% 
FTDG 44.0% 1.7% 76.7% 
 
 
Figure 3: Antimicrobial activity against clinical isolates of Gardnerella vaginalis collected from 
women with a history if Preterm Delivery 
 
 
Figure 4: Antimicrobial activity against clinical isolates of Gardnerella vaginalis collected from 
women with a history if Full term Delivery 
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3.4.3. Frequency of Biotypes 
Gardnerella vaginalis isolates were characterised into eight biotypes using the biochemical tests for 
lipase and β-galactosidase activity and hippurate hydrolysis. Table 8 illustrates the varying frequencies 
at which biotypes were detected. In PTDG biotype 5 occurred most frequently at 24.7%, followed by 
biotype 7 at 23.3% and biotype 2 at 17.8%. Biotypes 1 and 4 occurred less frequently at 4.1% each. A 
significant association was observed between previous PTD and FTD for biotypes (p = 0.003), with 
biotypes 2, 4 and particularly 5, showing the most significant difference between PTD and FTD (Table 
8). Similarly; in FTDG certain biotypes prevailed. However, here biotypes 3 and 4 occurred most 
frequently at 20% each, with biotype 4 demonstrating a significant difference (p = 0.017), while biotype 
2 was detected the least frequently at 5%.  Interestingly to note biotypes 2, 3 and 4 are characterised by 
lipase and β-galactosidase activity, while 5 and 7 are characterised as having negative reactions for these 
tests.  
 
Table 8: Frequency of biotypes in PTDG and FTDG 
  
  
Biotype (%)  
1 2 3 4 5 6 7 8
Significance 
level 
PTDG (n=73) 3 (4.1) 13 (17.8) 5 (6.8) 3 (4.1) 18 (24.7) 7 (9.6) 17 (23.3) 7 (9.5) 
p = 0.003 
FTDG (n=60) 5 (8.3) 3 (5.0) 12 (20.0) 12 (20.0) 5 (8.3) 4 (6.7) 10 (16.7) 9 (15.0)
Significance levels p = 0.011 p = 0.079 p = 0.017 p = 0.005  
 
 
3.4.4. Metronidazole and Clindamycin resistant biotypes 
Of all the isolates Biotype 7 was the most resistant to Metronidazole (27/133, 20.3%), however biotype 
5 was more resistant in PTDG (24.7%)  and  biotypes 3 and 4 (20.0%) in FTDG. The one isolate that 
was sensitive to Metronidazole, from FTDG,  was characterised as biotype 5. Within FTDG, no 
statistically significant association between biotypes and Metronidazole resistance was observed (p = 
0.283; Figure 5). 
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Figure 5: Metronidazole resistance associated with biotypes in FTD and PTD 
 
Considering that Clindamycin resistance was low, in PTDG biotype 5 had the highest resistance to 
Clindamycin (9.6%), whereas biotype 4 was the most resistant strain in FTDG.  
In both PTDG and FTDG, no statisically significant association between Clindamycin resistance and 
biotypes was observed (Figure 6). 
 
  
Figure 6: Clindamycin resistance associated with biotypes in FTD and PTD 
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3.5. RISK FACTORS 
The prevalence BV, AV, clue cells, G. vaginalis and Metronidazole and Clindamycin resistant strains 
were compared to various demographic and clinical data to determine which confounding factors serves 
as risk factors for the above conditions.  
 
3.5.1 Location of population groups 
BV was common in women attending MMH, with the highest percentage observed in FTDG 
(22.7%). In PTDG AV was diagnosed most frequently in subjects attending MMH, while the 
highest frequency of AV in FTDG was observed at KMOU (Table 9). The highest prevalence of 
G. vaginalis In PTDG was observed at MMH (35.9%), while for FTDG the prevalence of G. 
vaginalis was highest at KMOU (37.9%).  
Although no statistically significant association was observed between location of populations 
where sample collection took place and Metronidazole resistance, the highest percentage of 
resistant strains were isolated from 37% of PTDG subjects at MMH, and 40.7% of FTDG at 
KMOU. Similar results were observed with Clindamycin resistance (Table 9). 
 
3.5.2 Age 
BV, G. vaginalis and Metronidazole resistant strains was more prevalent in the19-25year age 
group (Table 9) with BV diagnosed in 12.0% in FTDG and in 11.9% of PTDG; G. vaginalis was 
isolated in 66.66% of FTDG subjects and 69.23% of PTDG, no statistically significant 
association was observed between groups. 
In PTDG, AV was most prevalent in the 26-30 year age range (10.6%), whereas it was more 
prevalent in the 19-25 years age range in FTDG (8.7%; Table 9). 
G. vaginalis was rarely detected in the ≥41 year’s age group (1.3% of PTDG and 1.5% of 
FTDG). Clindamycin resistant strains were more common in the 26-30 year age groups 
 
3.5.3 Marital status 
In both groups, BV and AV (13.9% PTDG and 14.7% FTDG) was more prevalent in single 
women, but there was no statistically significant association between relationship status and BV 
(p = 0.288; Table 9). In FTDG, G. vaginalis was detected more from women who were 
unmarried (53.0%) than married (31.8%) or in a relationship (boyfriend; 4.5%). Whereas in 
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PTDG, there was a small difference in the isolation of G. vaginalis in those who were single 
(47.4%) and those who were married (48.7%), but this was not of statistical significance (Table 
9). 
In PTDG, Metronidazole and Clindamycin resistance was highest in those who were married, 
whereas in FTDG resistance was highest in single women.  
 
3.5.4 Education 
Both BV and G. vaginalis was more frequently detected in women with secondary school 
education, but no statistical significant association was observed between BV and education 
level (Table 9).  
 
3.5.5 Smoking & Alcohol consumption 
In PTDG, BV was diagnosed in 42 (27.8%) of non-smokers and 45 (29.8%) of non-drinkers. In 
FTDG BV was diagnosed in 46 (30.9%) of non-smokers and 43 (29.1%) of non-drinkers in the 
FTDG (Table 9).  
Almost equal numbers of G. vaginalis-positive women, 84.6% of PTDG and 84.4% of FTDG, 
were non-smokers, while fewer G. vaginalis-positive women from FTDG (10.61%) smoked 
compared to 15.4% of PTDG women. G. vaginalis was isolated in only 5.1% of PTDG and 
15.2% of FTDG subjects who consumed alcohol (Table 9).  
 
3.5.6 History STI & HIV status 
For both PTDG and FTDG subjects, the prevalence of BV was highest in women who were not 
previously diagnosed with an STI, 23.2% and 23.3% respectively. The prevalence of BV was 
significantly low in HIV-positive subjects (p = 0.004; Table 9).  
A small percentage of G. vaginalis-positive women were previously diagnosed with an STI, but 
the percentage of PTDG (15.4%) was higher than FTDG (12.1%). 
G. vaginalis was detected in 28.2% of HIV-positive women in PTDG and in 27.3% of HIV-
positive women in FTDG (Table 9).     
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3.5.7 Clinical symptoms 
BV prevalence was much greater in subjects presenting with vaginal discharge than urinary 
symptoms (Table 9). 
In PTDG, majority of women who presented with vaginal discharge (64.1%) harboured G. 
vaginalis and this was less than those in FTDG (72.7%). In addition, more FTDG subjects with 
G. vaginalis colonization (15.2%) presented with urinary symptoms than PTDG (1.3%). G. 
vaginalis was isolated from more healthy women in the PTDG (29.49%) than FTDG (12.1%). 
In both PTDG and FTDG, Metronidazole resistance was high in those presenting with urinary 
symptoms, whereas Clindamycin resistance was highest in those with vaginal discharge (Table 
9).    
 
3.5.8 Personal Hygiene 
BV was frequently detected in women making use of hand washing in a wash basin, which is not 
an adequate cleansing method. Similarly, G. vaginalis was isolated mostly in women who 
washed in a washing basin, 74.4% in PTDG and 71.2% in FTDG. While smaller percentages 
showered and bathed (Table 9). Metronidazole and Clindamycin resistance was highest in those 
making use of hand-washing in a wash basin as a bathing option (Table 9).  
 
None of the women diagnosed with BV or from whom G. vaginalis was isolated practiced 
douching.  
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Table 9: Risk factors for BV and demographic and clinical data 
 
Significance 
levels 
PTDG 
 
FTDG 
 
BV 
n= 151 
Clue cells 
n= 151 
AV 
n= 151 
GV 
n=78 
Antibiograms 
BV 
n= 150 
Clue cells 
n= 150 
AV 
n= 150 
GV 
n=66 
Antibiograms 
Metro. 
n=73 
Clinda. 
n=18 
Met.  
n=59 
Clin. 
n=14 
Locations 
 MMH 
 KMOU 
 MPP 
 GUG 
p = 0.000 
 
18 (11.9) 
8 (5.3) 
6 (4.0) 
15 (9.9) 
 
11 (7.3) 
2 (1.3) 
1 (0.7) 
7 (4.6) 
 
20 (13.2) 
6 (4.0) 
9 (6.0) 
7 (4.6) 
 
28 (35.9) 
14 (17.9) 
19 (24.4) 
17 (21.8) 
 
 
27 (37.0) 
13 (17.8) 
18 (24.7) 
15 (20.5)  
 
 
6 (33.3) 
2 (11.1) 
4 (22.2) 
6 (33.3) 
 
 
34 (22.7) 
17 (11.3) 
15 (10.0) 
8 (5.3) 
 
3 (2.0) 
6 (4.0) 
4 (2.7) 
4 (2.7) 
 
 
6 (4.0) 
14 (9.3) 
12 (8.0) 
5 (3.3) 
 
14 (21.2) 
25 (37.9) 
19 (28.8) 
8 (12.1) 
 
 
14 (23.7) 
24 (40.7) 
15 (25.4) 
6 (10.2) 
 
 
1 (7.1) 
6 (42.9) 
5 (35.7) 
2 (14.3) 
 
 
Age Distribution 
 19-25 Years 
 26-30 Years 
 31-35 Years 
 36-40 Years 
 ≥41 Years 
p = 0.785 
 
18 (11.9) 
15 (9.9) 
11 (7.3) 
2 (1.3) 
0 (0.0) 
 
7 (4.6) 
7 (4.6) 
5 (3.3) 
1 (0.7) 
0 (0.0) 
 
13 (8.6) 
16 (10.6) 
8 (5.3) 
2 (1.3) 
2 (1.3) 
 
26 (33.3) 
28 (35.9) 
17 (21.8) 
6 (7.7) 
1 (1.3) 
 
 
24 (32.9) 
27 (37.0) 
17 (23.3) 
5 (6.8) 
0 (0.0) 
 
 
7 (38.9) 
7 (38.9) 
3 (16.7) 
1 (5.6) 
0 (0.0) 
 
 
18 (12.0) 
17 (11.3) 
12 (8.0) 
0 (0.0) 
1 (0.7) 
 
3 (2.0) 
9 (6.0) 
3 (2.0) 
1 (0.7) 
1 (0.7) 
 
13 (8.7) 
10 (6.7) 
8 (5.3) 
5 (3.3) 
0 (0.0) 
 
20 (30.3) 
23 (34.8) 
16 (24.2) 
4 (6.1) 
1 (1.5) 
 
20 (33.9) 
19 (32.2) 
13 (22.0) 
5 (8.5) 
0 (0.0) 
 
 
5 (35.7) 
6 (42.9) 
3 (21.4) 
0 (0.0) 
0 (0.0) 
 
Marital Status  
 Single 
 Married 
 Boyfriend 
p = 0.244 
 
25 (16.6) 
21 (13.9) 
1 (0.7) 
 
9 (6.0) 
12 (7.9) 
0 (0.0) 
 
21 (13.9) 
19 (12.6) 
2 (1.3) 
 
37 (47.4) 
38 (48.7) 
3 (3.8) 
 
33 (45.2) 
3 (4.1) 
37 (50.7) 
 
6 (33.3) 
1 (5.6) 
11 (61.1) 
 
27 (18.0) 
17 (11.3) 
2 (1.3) 
 
 
8 (5.3) 
7 (4.7) 
1 (0.7) 
 
22 (14.7) 
10 (6.7) 
2 (1.3) 
 
35 (53.0) 
21 (31.8) 
3 (4.5) 
 
32 (54.2) 
2 (3.4) 
18 (30.5) 
 
8 (57.1) 
0 (0.0) 
6 (42.9) 
Level of Education  
 Primary school 
 Secondary school 
 Tertiary/University 
p = 0.092 
 
3 (2.0) 
42 (27.8) 
1 (0.7) 
 
1 (0.7) 
19 (12.6) 
1 (0.7) 
 
2 (1.3) 
38 (25.2) 
1 (0.7) 
 
3 (3.8) 
72 (92.3) 
2 (2.6) 
 
1 (1.4) 
68 (93.2) 
3 (4.1) 
 
0 (0.0) 
17 (94.4) 
1 (5.6) 
 
2 (1.3) 
47 (31.3) 
0 (0.0) 
 
0 (0.0) 
17 (11.3) 
0 (0.0) 
 
2 (1.3) 
33 (22.0) 
2 (1.3) 
 
5 (7.6) 
58 (87.9) 
3 (4.5) 
 
5 (8.5) 
51 (86.4) 
3 (5.1) 
 
1 (7.1) 
13 (92.9) 
6 (42.9) 
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Employment 
 Yes 
 No  
p = 0.527 
 
17 (11.3) 
30 (20.0) 
  
8 (5.3) 
13 (8.6) 
 
15 (9.9) 
27 (17.9) 
 
27 (34.6) 
50 (64.1) 
 
25 (34.2) 
47 (64.4) 
 
6 (33.3) 
12 (66.7) 
 
13 (8.7) 
36 (24.0) 
 
8 (5.3) 
9 (6.0) 
 
 
13 (8.7) 
24 (16.0) 
 
26 (39.4) 
40 (60.6) 
 
23 (39.0) 
36 (61.0) 
 
7 (50.0) 
7 (50.0) 
Cigarette Smoking 
 Yes 
 No 
p = 0.007 
 
5 (3.3) 
42 (27.8) 
 
3 (2.0) 
18 (12.0) 
 
10 (6.6) 
32 (21.2) 
 
12 (15.4) 
66 (84.6) 
 
11 (15.1) 
62 (84.9) 
 
3 (16.7) 
15 (83.3) 
 
3 (2.0) 
46 (30.7) 
 
0 (0.0) 
17 (11.3) 
 
1 (0.7) 
36 (24.0) 
 
7 (10.6) 
59 (89.4) 
 
7 (11.9) 
52 (88.1) 
 
0 (0.0) 
14 (100.0) 
Alcohol consumption 
 Yes 
 No 
p = 0.319 
 
2 (1.3) 
45 (29.8) 
 
1 (0.7) 
20 (13.2) 
 
4 (2.6) 
38 (25.2) 
 
4 (5.1) 
74 (94.9) 
 
4 (5.5) 
69 (94.5) 
 
1 (5.6) 
17 (94.4) 
 
6 (4.0) 
43 (28.7) 
 
2 (1.3) 
15 (10.0) 
 
4 (2.7) 
32 (21.3) 
 
10 (15.2) 
55 (83.3) 
 
8 (13.6) 
50 (84.7) 
 
0 (0.0) 
14 (100.0) 
STIΦ 
 Yes 
 No 
 
 
8 (5.3) 
35 (23.2) 
 
7 (4.6) 
12 (7.9) 
 
7 (4.6) 
30 (19.9) 
 
12 (15.4) 
55 (70.5) 
 
12 (16.4) 
50 (68.5) 
 
4 (22.2) 
10 (55.6) 
 
9 (6.0) 
35 (23.3) 
5 (3.3) 
11 (7.3) 
 
4 (2.7) 
27 (18.0) 
 
8 (12.1) 
52 (78.8) 
 
7 (11.9) 
46 (78.0) 
 
3 (21.4) 
10 (71.4) 
HIVΦ 
 Positive 
 Negative  
 
 
19 (12.6) 
23 (15.2) 
 
9 (6.0) 
9 (6.0) 
 
15 (9.9) 
24 (15.9) 
 
22 (28.2) 
49 (62.8) 
 
21 (28.8) 
48 (65.8) 
 
4 (22.2) 
14 (77.8) 
 
13 (8.7 
32 (21.3) 
 
3 (2.0) 
13 (8.7) 
 
12 (8.0) 
20 (13.3) 
 
18 (27.3) 
42 (63.6) 
 
16 (27.1) 
38 (64.4) 
 
4 (28.6) 
9 (64.3) 
Clinical Symptoms 
 Vaginal discharge 
 Urinary symptoms 
p = 0.657 
 
27 (17.9) 
1 (0.7) 
 
1 (0.7) 
12 (7.9) 
 
2 (1.3) 
23 (15.2) 
 
50 (64.1) 
1 (1.3) 
 
 
1 (1.4) 
45 (61.6) 
 
10 (55.6) 
0 (0.0) 
 
38 (25.3) 
7 (4.7) 
 
2 (1.3) 
14 (9.3) 
 
2 (1.3) 
33 (22.0) 
 
48 (72.7) 
10 (15.2) 
 
9 (15.3) 
42 (71.2) 
 
13 (92.9) 
0 (0.0) 
Personal Hygiene 
Bathing option 
 Hand wash 
 Bath 
 Shower 
DouchingΦ 
 Yes 
 No 
 
 
 
p = 0.244 
 
 
38 (25.2) 
6 (4.0) 
3 (2.0) 
 
0 (0.0) 
13 (8.6) 
 
 
17 (11.3) 
3 (2.0) 
1 (0.7) 
 
0 (0.0) 
6 (4.0) 
 
 
31 (20.5) 
10 (6.6) 
1 (0.7) 
 
0 (0.0) 
12 (7.9) 
 
 
58 (74.4) 
15 (19.2) 
5 (6.4) 
 
0 (0.0) 
16 (20.5) 
 
 
54 (74.0) 
14 (19.2) 
5 (6.8) 
 
0 (0.0) 
16 (21.9) 
 
 
13 (72.2) 
4 (22.2) 
1 (5.6) 
 
0 (0.0) 
0 (0.0) 
 
 
36 (24.0) 
11 (7.3) 
1 (0.7) 
 
0 (0.0) 
16 (10.6) 
 
 
14 (9.3) 
3 (2.0) 
0 (0.0) 
 
0 (0.0) 
4 (2.7) 
 
 
27 (18.0) 
9 (6.0) 
1 (0.7) 
 
0 (0.0) 
8 (5.3) 
 
 
47 (71.2) 
12 (18.2) 
5 (7.6) 
 
0 (0.0) 
25 (37.9) 
 
 
41 (69.5) 
11 (18.6) 
5 (8.5) 
 
0 (0.0) 
23 (39.0) 
 
 
10 (71.4) 
3 (21.4) 
1 (7.1) 
 
0 (0.0) 
0 (0.0) 
BV: Bacterial vaginosis; AV: Aerobic vaginitis, GV: G. vaginalis, Metro: Metronidazole, Clind: Clindamycin 
Φ: unable to calculate significant levels due to abundance of missing data
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3.6. ASSOCIATION OF MICROSCOPY WITH PREVALENCE OF GARDNERELLA 
VAGINALIS & BIOTYPES 
 
3.6.1. G. vaginalis isolates 
A cross-examination was done to determine how many women diagnosis with BV were colonised with 
G. vaginalis, and whether there was a difference between PTDG and FTDG (Figure 7).   
Among FTDG, more than a third (39.3%) of the women who were not colonised by G. vaginalis, 
presented with normal vaginal flora, while this was seen in only a small number (12.7%) of G. vaginalis 
colonizers. On the other hand, the G. vaginalis-positive women were more prone to having vaginal flora 
indicative of bacterial vaginosis (22.7%) and fewer G. vaginalis-negative women had abnormal vaginal 
flora. Low numbers of both G. vaginalis-positive (8.7%) and G. vaginalis-negative (6%) presented with 
intermediate flora.  
Similar results were seen among PTDG. G. vaginalis-negative women had predominantly normal flora 
(36.4%) and while there were more G. vaginalis-negative women presenting with intermediate flora 
(6.62%, 10/151), a small number (5.3%) had flora representative of BV. In addition, BV was more 
prevalent among G. vaginalis-positive women (25.8%) when compared to normal flora (15.9%) in 
PTDG (Figure 7).  
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Figure 7: Prevalence of Gardnerella vaginalis compared with Microscopy 
NF = normal flora, IF = intermediate flora, BV = bacterial vaginosis; PTDG = preterm birth (n=151), FTDG = normal birth (n=150) 
 
3.6.2. Biotypes associated with BV and AV 
As demonstrated in Table 10,   biotypes were cross referenced with the microscopic examinations for 
AV and BV.  
In PTDG, a statistically significant association was observed between a history of PTD and BV (p = 
0.000) and AV (p = 0.000). Biotype 2 was the dominant biotype in patients with BV (19.2%), whereas 
biotype 8 prevailed in patients with AV (16.7 %; Figure 8). 
However in FTDG, biotype 4 dominated both in patients with BV (18.4%) and AV (10.8%; Figure 8), 
but this association was only significant with BV (p = 0.000; Table 10). 
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Table 10: Association between microscopy suggestive of BV and AV, and biotypes 
 PTDG FTDG 
BV n=47 AV n=42 BV n=49 AV n=37 
1 2 (4.3) 1 (2.4) 2 (4.1) 2 (5.4) 
2 9 (19.2) 6 (14.3) 3 (6.1) 1 (2.7) 
3 3 (6.4) 2 (4.8) 3 (6.1) 3 (8.1) 
4 1 (2.1) 0 (0.0) 9 (18.4) 4 (10.8) 
5 7 (14.9) 6 (14.3) 4 (8.2) 2 (5.4) 
6 5 (10.6) 4 (9.5) 2 (4.1) 2 (5.4) 
7 7 (14.9) 6 (14.3) 7 (14.3) 3 (8.1) 
8 3 (6.4) 7 (16.7) 4 (8.2) 3 (8.1) 
Significance level p = 0.000 p = 0.000 p = 0.000 p = 0.618 
 
 
 
Figure 8: Cross-analysis of biotypes with BV observed in patients with history of preterm delivery 
 
3.6.3. Antibiograms associated with BV  
Metronidazole and Clindamycin resistant strains were cross-referenced with Nugent scoring results to 
determine if antibiotic resistance is associated with BV. For both PTDG and FTDG, Metronidazole 
resistance was demonstrated in approximately 50% of subjects diagnosed with BV (37 of 73 and 29 of 
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60 respectively). Metronidazole resistance was observed in subjects with normal vaginal micro-flora, but 
to a lesser degree (31.5%; Figure 9). 
 
 
 
Figure 9: Association of metronidazole resistant strains of G. vaginalis in patients with BV 
 
Taking into account that fewer subjects demonstrated resistance to Clindamycin, naturally Clindamycin 
resistance would be low among BV-positive subjects (11.0% in PTDG and 13.3% in FTDG; Figure 10), 
and no statistically significant association between BV and neither Metronidazole nor Clindamycin 
resistance was observed. 
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Figure 10: Association of clindamycin resistant strains of G. vaginalis in patients with BV 
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3.7. ACCURACY OF MICROSCOPY AND G. VAGINALIS FOR DETECTING BV 
The Nugent scoring system is often used to diagnose BV in a research or clinical laboratory. 
Furthermore, the detection of G. vaginalis from patients suspected of having BV is often used as a 
predictor of preterm delivery. However, G. vaginalis can also be isolated from healthy patients; 
therefore the accuracy of G. vaginalis detection as an indicator of BV was investigated. 
 
When Nugent scoring was used as the reference standard, the PPV for isolating G. vaginalis in culture 
was 84.7% with a sensitivity of 76.04%.  The specificity (87.3%) and PPV (82.98) of the Nugent score 
was highest in mothers with a history of PTD compared with FTD mothers with an accuracy of 62% 
(Table 11). 
 
Table 11: Comparison of Nugent scoring with culture  
Test Sens. Spec. PPV NPV Acc ODDS+ ODDS- 
Culture 76.04 72.6 84.68 83.21 22 3.13 0.2 
PTDG 61.90 87.30 82.98 69.62 62.25 -25.4 0.4 
FTDG 69.39 75.64 64.15 79.73 62 -6.25 0.1127 
Sens.: sensitivity, Spec.: specificity, Acc.: Percentage accuracy, PPV: positive predictive value, NPV: negative predictive value, Odds +: positive odds ratio, 
Odds -: negative odds ratio. 
 
When culture was used as the reference standard, the sensitivity for a positive Nugent score dropped to 
62.93% while the specificity increased 83.2%. Unlike the Nugent score, culture was not able to 
differentiate between PTDG and FTDG mothers (Table 12). 
 
Table 12: Comparison of Culture for Gardnerella with microscopy 
Test Sens. Spec. PPV NPV Acc ODDS+ ODDS- 
Nugent 62.93 83.21 76.04 72.61 22 -20.28 0.37 
PTDG 69.39 71.08 61.9 87.30 31.33 -1.69 0.143 
FTDG 64.15 79.73 69.39 75.650 21.38 -15.58 0.31 
Sens.: sensitivity, Spec.: specificity, Acc.: Percentage accuracy, PPV: positive predictive value, NPV: negative predictive value, Odds +: positive odd ratio, 
Odds -: negative odd ratio. 
 
 
 
 
 
55 
 
 
Chapter 4: Discussion & Conclusion 
 
Bacterial vaginosis (BV) has been shown to be a risk factor in adverse pregnancy outcomes (Holst et 
al.et al.., 1994; Hillier et al., 1995; Lliahi-Camp et al., 1996). Previous studies (Krohn et al., 1989; 
Kimberlin & Andrews, 1998) have demonstrated that Gardnerella vaginalis plays a major role in the 
development of BV. Thus, we embarked on a study to establish the prevalence of BV and G. vaginalis 
in pregnant women with and without a history of preterm delivery, in order to establish an association of 
BV and G. vaginalis with adverse pregnancy outcomes. In addition, G. vaginalis was characterised by 
biotyping to establish which biotypes are most prevalent in this Western Cape population. 
 
4.1. RISK FACTORS FOR BV 
Adverse pregnancy outcomes, such as preterm delivery (PTD), have become a rare event in 
industrialised countries, but remain a serious problem in the developing world. In 2005 the highest rates 
of preterm birth reported were in Africa (11.9%), while the lowest were in Europe (6.2%). Not only does 
PTD impose a risk of maternal and/or neonatal mortality, but it may also cause severe, long-term 
morbidity for the infant, which could also lead to several chronic, degenerative diseases later in life (van 
den Broek et al., 2005; Beck et al., 2009; Svensson et al., 2009; Goldenberg & McClure, 2010).  
 
There are several factors that can have an impact on pregnancy outcome. Maternal demographics, such 
as race, education, socioeconomic status, marital status and frequency of vaginal or intra-uterine 
infections, are probably the most important factors that could pose a health risk to mother and infant 
(Filho et al., 2010; Marrazzo, 2011). It is important to identify factors that could predispose women to 
BV acquisition to enable screening of those at risk, and therefore prompt administration of necessary 
treatment (Thorsen et al., 2006). A possible explanation for race being a risk factor for BV acquisition 
can be attributed to the differences in functioning of the hypothalamic-pituitary-adrenal (HPA) axis in 
black women compared to white women. The HPA axis is respomsible for controlling the human stress 
response, and is regulated by corticotrophin-releasing hormone (CRH). During pregnancy, CRH is 
produced in the placenta, decidua and foetal membranes. In addition to having a higher concentration of 
CRH, there are several CRH polymorphisms present in black women only, that contributes to their 
increased risk for BV (Mastorakos & Ilias, 2000; Ryckman et al., 2009). In our study, the locations from 
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which participants were recruited, was an indication of the population groups they served, the majority 
of which live under challenging socio-economic conditions. Although we did not have refined data on 
the ethnicity of participants, we do know that the four locations serve mainly black and coloured 
communities. Taking this into consideration, we were able to demonstrate an association between a 
history of PTD and location of population. It has previously been demonstrated that black women have 
approximately double the chance of delivering preterm compared to their white counterparts 
(Goldenberg & McClure, 2010; MacDorman, 2011). In addition to a general lack of resources in black 
communities, the possible role of specific gene polymorphisms associated with African ancestry, have 
been the attributing factors (Anachebe, 2006; Tsai et al., 2012). 
 
Compounding the problem is that low socioeconomic status is significantly associated with an increased 
prevalence of BV among African American women (Paul et al., 2008). Socioeconomic status plays a 
huge role in whether or not a woman will have a successful pregnancy. If she is uneducated, she will not 
likely be able to make informed decisions regarding prenatal care. Likewise, if she is unemployed or 
holds a low income job, she will not have the necessary access to adequate prenatal care. Although our 
study population was reasonably well educated, they generally held low income jobs. Access to free 
antenatal care, reduced the risk for PTD in this study population, although other socioeconomic factors 
may have been implicated.  Previous studies in Southern Africa detected BV in 52% of pregnant women 
from a mainly black underprivileged population in Kwa-zulu Natal, (Govender et al., 1996), whereas in 
The Gambia, a BV prevalence of 47.6% was reported (Demba et al., 2005). Govender et al. (1996) 
attributed their high incidence to low socio-economic conditions often linked to promiscuity. Although 
there are definitely demographic similarities between Govender’s study population and the current study 
population, the two studies were performed in different regions of the country. In addition, Govender’s 
study was performed more than ten years ago and since then, there has been a great improvement in the 
health system in this country, as well as a greater body of knowledge with regard to women and 
pregnancy issues. According to data obtained from National Health and Nutrition Examination Survey 
(Allsworth and Peipert, 2007), BV was 3.13 times more prevalent in African American women than 
non-Hispanic white women. However BV was just as prevalent in our “black” population as the general 
American population.  
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Sexual behaviour, more specifically number of sexual partners and age of first intercourse, have been 
associated with an increased prevalence of BV. In our study, provision was not made to obtain such 
information as it was not required to fulfil the objectives. We did however collect information pertaining 
to relationship status. In the study, “single” was regarded as women not currently in a relationship. More 
women (48.2%) fell into this category than those who were married (44.5%). We observed BV more 
frequently in single women, who could possibly have had multiple sexual partners, thereby supporting 
the notion that BV is associated with increased number of sexual partners (Allsworth & Peipert, 2007). 
However, in the past, being married was an indication that a couple is monogamous and therefore not at 
risk of sexually transmitted infections (STIs) associated with promiscuity, but this is no longer 
necessarily the case. Even though infections may not always produce symptoms, abnormal vaginal 
presentation is generally a concern during pregnancy as it could be seen as a risk factor for PTD.  
 
The general prevalence of HIV-positive subjects was low (24.58%), with a few not willing to reveal 
their HIV-status. In addition, most participants (72.43%) claimed not to have had an STI previously; 
therefore HIV status and previous STI could not be associated with a history of PTD.  However clinical 
symptoms, such as vaginal discharge, were strongly associated with a history of PTD, as more than half 
of participants presented with a vaginal discharge. Although the frequency of BV was low in HIV 
positive subjects (13.9%), we were able to demonstrate an association between BV and HIV status. 
However; BV did not appear to affect a woman’s chance of acquiring HIV in this population.  
 
Previous studies have indicated an increase in the prevalence of BV with age (Larsson et al., 2007) . In 
our study, as with the study by Allsworth & Peipert (2007), we found BV prevalence to decrease with 
age. The difference between this study and those indicating increased BV prevalence with age, is that 
while we sampled only pregnant women, their subjects included all women attending sexually 
transmitted disease clinics. STIs are generally more common among younger women, therefore the fact 
that BV prevalence increases with age has been used to defend the argument that BV is not a STI 
(Larsson et al., 2007). We now know that although it may be sexually transmitted, its aetiology is due to 
an alteration in the balance of the vaginal micro-flora. Therefore BV may be considered a “sexually 
enhanced disease”, with frequency of intercourse playing a vital role in BV transmission (Verstraelen et 
al., 2010).  
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In this study, age was not associated with adverse outcomes, but it appears increased parity may be 
associated with PTD. It is recognized that the interaction between maternal age and parity is a risk factor 
for adverse perinatal outcomes, including preterm birth (PTB), such that young women who have given 
birth more than twice and older women experiencing their first pregnancy have greater risks (Schempf et 
al., 2007).  
 
Very few of our participants were smokers (13.62%) or alcohol consumers (9.63%). Although both 
prenatal alcohol consumption and maternal smoking have both been shown to increase the risk of PTD, 
(Ng et al., 2006; Aliyu et al., 2010), we were only able to demonstrate an association between smoking 
and a history of adverse pregnancy outcomes in this study. In addition, smoking also increases the risk 
of BV acquisition through various possible pathways. Smoking not only curbs the growth of lactobacilli 
(Livengood, 2009), but it also affects the genetic vulnerability for BV development as a result of its 
ability to affect stress-related genes (Ryckman et al., 2009). However, as a result of a small number of 
reported smokers in our study, smoking was not indicated as a risk factor for BV for this population.   
 
Observational studies have demonstrated a strong association between vaginal douching and bacterial 
vaginosis. Douching is a process that involves rinsing the vagina as a means of cleansing it. This process 
is risky as it changes the delicate chemical balance and micro-flora composition in the vagina, in so 
doing, making a woman participating in this practice more prone to BV.  It is not clear whether 
douching increases the risk of BV or whether BV symptoms lead women to douche (Brotman et al., 
2008; Luong et al., 2010). A great number of our study population did not respond to the question 
pertaining to douching, perhaps because they were not familiar with the practice. As a result we could 
not establish an association between douching and BV, as data was insufficient. We were however able 
to get an indication of the level of personal hygiene practiced by participants. Many of them reside in 
informal settlements where proper sanitation is lacking. Even though we observed an increased 
prevalence of BV in women participating in hand washing in a wash basin compared to bathing or 
showering, this was not associated with an increased chance of developing BV.  
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4.2. PREVALENCE OF G. VAGINALIS IN BV 
Upon sample collection, participants were examined for clinical signs of infection, including urinary 
tract infections and vaginal discharge, both of which are a major risk for PTD (Onderdonk et al., 2003; 
Menon et al., 2011).  
 
The literature is filled with reports on the relationship between infections of the lower genital tract and 
spontaneous preterm birth. While numerous available reports are conflicting, BV has consistently been 
associated with adverse pregnancy outcomes, including preterm labour, pelvic inflammatory disease, 
and delivery of low birth weight infants. BV is a surprisingly prevalent condition, affecting 
approximately 3 million women annually (Wang, 2000). The exact sequence of events that causes the 
onset of BV is unknown, but BV may possibly have a multi-factorial aetiology and occurs as a result of 
microbial colonisation and alteration that leads to inflammation of the upper genital tract (Kimberlin and 
Andrews, 1998).  
 
Generally Amsel’s criteria are implemented to diagnose BV within a clinical setting. A patient is 
considered positive for BV if any three of the four Amsel criteria are met. However, the aim of this 
study was to determine the accuracy of Nugent scoring and culture to predict BV, and as a result of time 
and resource limitations, we were unable to execute all of the Amsel criteria in making a clinical 
diagnosis of BV and instead examined for “clue cells” on Gram-stained slides in conjunction with 
Nugent scoring. A subject was positively diagnosed with “clue cells” if ≥20% of epithelial cells were 
studded with variable Gram-positive coccobacilli.  
 
We followed the suggestion by Spiegel (1991) to use Kopeloff’s  modification of the Gram stain with a 
safranin counterstain, as it aids in differentiating G. vaginalis from Bacteroides spp. The Kopeloff stain 
minimizes overdecolorisation of Gram-positive bacteria while simultaneously increasing the visibility of 
Gram-negative organisms (Libman et al., 2006).  Microscopic examination of Gram-stained slides is 
considered an accurate means of diagnosing BV (Schmidt and Hansen, 2000).  Gram stain score and 
diagnosis by the clinical criteria has low agreement. While Gram stain quantification is more sensitive, 
Amsel criteria are more specific (Livengood, 2009).Therefore Nugent scoring was selected to diagnose 
BV in this study. Clue cells were observed in 25.2% of slides examined, while BV was diagnosed from 
vaginal swabs in 31.13% of pregnant women with a history of preterm delivery and 23.7% of women 
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with a history of FTD, thereby indicating that not all BV-positive patients will demonstrate clue cells. 
Although less than half of subjects diagnosed with BV by Nugent scoring presented with “clue cells”, 
the two factors were highly associated with each other. Contrary to previous reports, in this study “clue 
cells” presented as a more specific (96.7%) indicator for BV, with very low sensitivity (32.3%). In 
support of this, it is worth noting that when clinically examined, asymptomatic women may not present 
with a discharge, amine odour may be masked by cervical mucus or blood and, while increased vaginal 
pH may be a sensitive predictor of BV, it is also characteristic of other vaginal conditions (Goyal et al., 
2005; Kwasniewska et al., 2006).  
 
In this study, Nugent scoring showed good specificity and sensitivity in diagnosing BV compared to 
culture techniques. Even though this study did not examine for other bacterial species associated with 
BV, our results support reports suggesting the crucial role of G. vaginalis in BV development. In a 
comparative study (Krohn et al., 1989), diagnosis by clinical criteria was compared to Gram stain, gas-
liquid chromatography, and G. vaginalis culture.  Of the women diagnosed with BV by finding three of 
the four Amsel clinical signs (21%), only 12% were diagnosed by Gram stain, 28% by gas-liquid 
chromatography, and 41% by G. vaginalis culture.  Since G. vaginalis is highly prevalent in women with 
BV, culture for G. vaginalis has a high sensitivity for predicting a diagnosis of BV while Gram staining 
vaginal smears is more specific because a positive culture may also be obtained from healthy women.  
 
Aerobic vaginitis (AV) refers to a vaginal condition where abnormal vaginal flora distinctly different 
from BV are observed. AV is characterised by the presence of aerobic micro-organisms such as group-B 
streptococci and Escherichia coli, and the absence of G. vaginalis (Donders, 2007). With the aid of a 
composite scoring system   (Donders et al., 2002), AV was diagnosed in 59.6% of participants classified 
as “intermediate” using Nugent scoring. In accordance to with previous reports, AV was significantly 
associated with PTD in this study (Lietich & Kiss, 2007).  
Although considered to be risk factors for PTD, microscopic examination for normal flora, intermediate 
flora, BV, AV and “clue cells” were not significantly different between PTDG and FTDG in this study. 
 
Microscopy cannot reliably differentiate bacterial morphotypes; therefore culture-based techniques 
using selective media are often used as a supplement to microscopy (Donders et al., 2009). Considering 
the polymicrobial nature of BV, the isolation of one micro-organism is not a specific indicator of BV 
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infection. In addition, culture techniques present with a number of shortcomings. It is time-consuming, 
requires the application of strict sample collection protocols, and is unable to isolate many of the species 
present in the biofilm observed in BV-positive patients (Srinivasan & Fredricks, 2008).  
 
The PPV was calculated to examine the probability of a positive G. vaginalis culture indicating BV 
infection (as diagnosed by Nugent scoring) and if a positive Nugent score could predict a positive G. 
vaginalis culture. In this study, Nugent scoring more accurately predicted BV, compared to isolation of 
G. vaginalis by culture techniques. In addition, we observed an association of 84.68% between BV and 
G. vaginalis. In PTDG, the likelihood of G. vaginalis being isolated from mothers who were diagnosed 
with BV by Nugent scoring was 82.98%, whereas in FTDG it was 64.15%. This difference can be 
attributed to the fact that in FTDG, there were endogenous asymptomatic carriers of G. vaginalis and/or 
that their overall microbial consortia were of a less virulent nature.   
 
4.3. THE SIGNIFICANCE  OF G. VAGINALIS IN BV 
G. vaginalis has for a long time been implicated as the sole cause of BV playing a pivotal role in its 
development (Turovskiy et al., 2011). However, it is also recovered from women with normal vaginal 
flora; thus casting doubt on its role in the pathogenesis of BV. Considering that G. vaginalis can be 
detected in healthy individuals, and that several other micro-organisms have been recovered from 
women diagnosed with BV, (e.g. Atopobium vaginae, Prevotella bivia, Mobiluncus mulieris, Veillonella 
spp., Peptostreptococcus spp. and Fusobacterium nucleatum), indicating G. vaginalis as the dominating 
pathogen in BV would not be entirely accurate (Tabrizi et al., 2006; Biagi et al.; 2009; Patterson et al., 
2010; Diao et al., 2011),  although it appears to be essential in the development of the BV biofilm. 
 
With that said several researchers have studied the relationship between BV and G. vaginalis and 
consistently isolated G. vaginalis from women diagnosed with BV (Holst et al., 1994; Goyal et al., 
2005).  Despite that fewer women diagnosed with BV were colonised with G. vaginalis in this study 
(40.6%), compared to the 87.5-100% reported by others (Aroutcheva et al., 2001; Bradshaw et al., 2006; 
Hale et al., 2006), G. vaginalis remains to be strongly associated with BV. How and why G. vaginalis 
plays such a critical role in the development of BV eluded many researchers, but with the development 
of advanced molecular techniques, the answers are becoming clearer. Analysis of vaginal biopsies 
revealed that BV is characterized by a dense biofilm on the vaginal epithelium dominated by G. 
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vaginalis as well as other fastidious anaerobes.  (Kimberlin and Andrews, 1998; Bradshaw et al., 2006; 
Allsworth & Peipert, 2007; Biagi et al., 2008; Menard et al., 2008; Marrs et al., 2012).  
 
The dominant role of G. vaginalis is attributed to its vast arsenal of virulence properties.  It boasts an 
ability to adhere to vaginal epithelial cells and form biofilms. It also demonstrates cytotoxicity and other 
factors essential to establishing an infection (Marrs et al., 2012). Adherence is an essential function in 
the pathogenesis of BV, as it aids in avoiding host defence clearance. The ability of G. vaginalis to 
adhere to vaginal epithelial cells is also an important first step in the formation of a biofilm. As with a 
dental biofilm, where specific bacteria have an affinity for the tooth pellicle, thereby enabling other 
bacterial species to attach, similarly  the adherence and bioflim formation by G. vaginalis allows 
avirulent opportunists, with minimal pathogenic potential, to become established in the vagina (Braga et 
al., 2010; Patterson et al., 2010). In addition, it has been shown that G. vaginalis has the ability to be 
internalised by vaginal epithelial cells. This intracellular localization, together with bioflim formation 
could allow G. vaginalis to escape the immune response, as well as exhibit antibiotic resistance (Marrs 
et al., 2012). Furthermore G. vaginalis produces phospholipase C and protease (Udayalaxmi et al., 
2011) that are able to damage oviduct mucosal surfaces and disable cilia function that  could possibly 
lead to infertility (Taylor-Robinson and Boustouller, 2011).  G. vaginalis also produces haemolysin, 
which serves as a food source for other bacterial species, and vaginolysin, a cytolysin that activates the 
protein kinase pathway in human epithelial cells resulting in subsequent cell death (Rottini et al., 1990; 
Gelber et al., 2008; Patterson et al., 2010). The role of vaginolysin in the pathogenesis of BV has been 
supported by the production of IgA antibodies against vaginolysin (Cauci et al., 2003). 
 
Even though virulence properties of G. vaginalis are not associated with a specific biotype, specific 
biotypes are associated with BV (Udayalaxmi et al., 2011). In this study, Biotype 7 was more frequently 
detected in participants diagnosed with BV. However, Biotype 2 occurred more frequently in women 
with a previous PTD (19.2%), while Biotype 4 was detected significantly more frequently in those with 
a history of FTD (18.4%). A previous study did not discriminate between specific groups, but associated 
Biotype 5 with BV; even though there were discrepancies in what was said in-text and what was 
represented in results (Briselden & Hillier, 1990). Conversely, Aroutcheva et al. (2001) clearly 
illustrated Biotypes 7 and 8 to be associated with BV.  
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Although biotyping is an old method of characterising G. vaginalis, with the aid of more advanced 
technologies, the specific tests for hippurate hydrolysis, lipase and β-galactosidase activity has 
improved. Unfortunately, the amount of available data on prevalence of biotypes in different regions is 
minimal and outdated. Biotype 5 was detected in all regions previously studied, except Bosnia (Piot et 
al., 1984; Briselden & Hillier, 1990; Numanovic et al., 2008; Udayalaxmi et al., 2011). Overall Biotype 
7 was the predominant biotype in this study, followed closely by Biotype 5. In women with a history of 
PTD and diagnosed with BV and AV, however, Biotypes 2 and 5 were increased while Biotype 4 was 
markedly decreased.  The only difference between Biotype 7 and Biotype 5 is the ability of Biotype 5 to 
hydrolyse hippurate.  
 
4.4. METRONIDAZOLE & CLINDAMYCIN RESISTANCE OF G. VAGINALIS 
Considering that BV increases the risk of PTD, there is a need for effective treatment strategies to 
reduce the PTD rate. Antibiotic therapy has shown success in eliminating BV in pregnancy (McDonald 
et al., 2007). The Centres for Disease Control recommends either oral or intravenous administration of 
Metronidazole or Clindamycin. Administration of these regiments has shown good success, but only for 
a short term. Approximately 30% of BV cases show recurrence at 3 months and approximately 50-80% 
at 1 year following therapy with either antibiotic. Recurring infection has been attributed to A. vaginae 
showing erratic susceptibility patterns to Metronidazole, the ability of A. vaginae and G. vaginalis 
bioflim to survive antimicrobial attack, as well as re-infection by another biotype (Menard et al., 2011). 
 
The big problem with re-administration of a similar antimicrobial is the chance of developing resistance. 
Metronidazole acts against anaerobic bacteria only and has therefore been the preferred choice of 
treatment for BV as it does not disturb the natural vaginal ecosystem (Austin et al., 2005; Livengood, 
2009). Since the early 1980s, Metronidazole has been used successfully to treat BV, but over the last 
decade Metronidazole resistance has become a frequent occurrence, including against G. vaginalis 
(Austin et al., 2005; Nagaraja, 2008; Tomusiak et al., 2011). This phenomenon was also observed in this 
study with Metronidazole resistance seen among 99% of G. vaginalis isolates. A. vaginae has been 
identified as the culprit for the Metronidazole resistance observed in BV-positive patients (Shopova et 
al., 2011) and although Metronidazole has been used successfully to treat BV, the last decade has 
revealed Metronidazole resistant  strains G. vaginalis not previously detected.   
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In women with a history of PTD, Biotypes 2, 5 and 7 was significantly resistant to Metronidazole, while 
biotypes 3, 4 and 8 showed Metronidazole resistance in those with a previous FTD. These findings 
correspond well to that of Aroutcheva et al. (2001). The resistance of G. vaginalis to Metronidazole in 
this study clearly indicates that the resistance to Metronidazole in the treatment of BV may be attributed 
to resistant strains of G. vaginalis and not only A. vaginae as previously reported. Compounding the 
problem is the emergence of Clindamycin resistant G. vaginalis. Although Clindamycin resistance was 
much lower (24%) than Metronidazole, in this study, in addition to Biotype 2, our findings are in 
accordance to that of Nagaraga (2008), who demonstrated Biotypes 4 and 5 showing Clindamycin 
resistance.   
 
As a result of resistance being on the rise, alternative therapy options have been investigated. Recently, 
Togni et al. (2011) demonstrated the in vitro effectiveness of Nifuratel which showed activity against 
the consortium of bacteria recognized in BV development, while simultaneously not harming the normal 
lactobacilli flora. Currently, two clinical trials are ongoing to compare it to standard BV treatments 
(Togni et al., 2011). The use of probiotics may change the way prophylactic treatments are conducted in 
the future since they pose no threat to either mother or foetus. 
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4.5. SUMMARY & CONCLUSION 
In this study, risk factors for BV were identified and the accuracy of microscopy and culture for the 
diagnosis of BV were compared.  Nugent scoring and the presence of “clue cells” did not show a 
significant difference between PTD and FTD groups. However, a significant association was detected 
when BV was compared with the isolation of G. vaginalis biotypes in the two groups (p = 0.000). While 
Biotype 7 specifically is particularly associated with BV, Biotype 2 appears to be associated with BV in 
women with a previous PTD.   In addition, Metronidazole-resistance was strongly indicated in the G. 
vaginalis strains isolated, with Clindamycin resistant strains emerging and the perceived role of G. 
vaginalis in BV confirmed. The null hypothesis is therefore rejected as G. vaginalis was isolated 
significantly more frequently in women diagnosed with BV. 
 
Attempts to recover many of the patients’ folders post partum in order to establish their pregnancy 
outcomes were unsuccessful. For this reason, the results presented in this study are limited to patient 
history of previous PTD or FTD only and are therefore not associated with the pregnancy outcome of 
the studied gestational period.   Failure to obtain the follow-up data may be attributed to:    
i. Obtaining permission from the correct authority to access patient folders. Each clinic has its own 
management who are not freely available for consultation, nor do they respond to written 
requests. Without their permission, we could not have access to many of the folders.  
ii. Most clinics are under-staffed with the result that staff are pushed to the limit and are not able to 
assist beyond their call of duty, even though many would like to do so.  
iii. Heavy workloads create inefficiencies regarding administration resulting in patient folders being 
misfiled, lost or not updated. 
iv. Many patients do not deliver at the clinic where they received antenatal care, and thus, even if 
the folder was available, pregnancy outcomes were not recorded. 
 
This limitation is indeed a pity since, had we managed to overcome these difficulties, it would have 
strengthened the predictive value of the study. An extension of this study to include the current 
pregnancy outcomes remains an option for future research. 
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Appendix A: Questionnaire 
 
Sample number: _________________________________________________ 
Folder number: ____________________________ KMOU   MPP        GUG 
Residence: ___________________________________________________ 
Age: ____________ Grav: _____________ Para: ________________ 
Height:_________________ Weight: _________________ 
 
PAST OBSTETRIC HISTORY 
Year Gestation/Birth weight1 Complications2 Neonatal Outcome3 
        
        
        
Please code as follows: 
1. GESTATION/BIRTHWEIGHT 
500-999g 1 
1000-1499g 2 
1500-1999g 3 
2000-2499g 4 
2500g+ 5 
unknown 6 
2. COMPLICATIONS 
Extreme multi-organ immaturity 1 
Hyaline membrane disease 2 
Intraventricular haemorrhage 3 
Necrotizing enterocolitis 4 
Pulmonary haemorrhage 5 
Hypoxic ischaemic 
encephalopathy 
6 
Meconium aspiration 7 
Septicaemia 8 
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Pneumonia 9 
Unknown 10 
3. NEONATAL OUTCOME 
Neonatal death 1 
Admitted to NICU 2 
Discharged 3 
 
 
 
 
PAST MEDICAL HISTORY 
Hypertension 1
Diabetes 2
Previous urinary tract infections 3
Other 4
If other, please specify:__________________ 
 
PAST SURGICAL HISTORY  
Myomectomy 1 
Ectopic 2 
Other uterine surgery 3 
Other non-gyneacological surgery 4 
If 3, please specify:_____________________________ 
If 4, please specify:_____________________________ 
 
 
DEMOGRAPHIC & LIFESTYLE FACTORS 
 
MARITAL STATUS 
Single   Married  Separated  Divorced  
 
Other (Please specify) _________________________________________________________ 
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HIGHEST LEVEL OF EDUCATION Please tick (√) the correct box 
G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 UNIVERSITY NONE 
                            
 
EMPLOYMENT  YES  NO 
If yes, please specify: ____________________________________________________________ 
 
SMOKING HABITS 
DO YOU SMOKE?          Y      N 
HOW MANY A DAY?     <10          10-20 >20 
HOW LONG HAVE YOU SMOKED? ______________________ 
DO YOU SMOKE DURING PREGNANCY? Y     N 
DO YOU USE TIK?          Y      N 
DO YOU USE ANY OTHER SUBSTANCES?         Y      N 
IF YES, PLEASE SPECIFY___________________________________ 
 
ALCOHOL USE 
DO YOU DRINK ALCOHOL          Y  N 
IF YES, WHAT DO YOU CONSUME?_________________________ 
 
HOW MANY DRINKS PER WEEK DO YOU DRINK? 
          <5  5-10          >10 
DO YOU DRINK DURING PREGNANCY?  Y        N 
 
REPRODUCTIVE HEALTH 
HIV STATUS  POS  NEG  UNKNOWN   CD4____________ HAART___________ 
HAVE YOU VER BEEN TREATED FOR A SEXUALLY TRANSMITTED DISEASE?    Y    N 
HOW MANY SEXUAL PARTNERS DO YOU HAVE CURRENTLY? ________________ 
IS THIS A NEW PARTNER?   Y  N 
CURRENT SYMPTOMS:  VAGINAL DISCHARGE  URINARY SYMPTOMS  
 
PERSONAL HYGIENE  
BATH   SHOWER   HANDWASH 
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OTHER ___________________________________________________________ 
 
DOUCHING  Y  N 
OTHER VAGINAL PRODUCTS? _______________________ 
 
UNDERWEAR?  NONE   COTTON  NYLON 
OTHER? ____________________________ 
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PERINATAL HEALTH SCREENING 
 
1. Have you had some very difficult things 
happen in the last year? 
 
2. Are you pleased about your pregnancy? 
 
3. Is your partner supportive? 
 
4. Have you had problems with depression, 
anxiety or panic attacks before? 
 
5. Is your partner or someone at home 
sometimes violent towards you? 
Yes No 
Yes No 
Yes No 
Yes No 
Yes No 
 
For total, add all shaded areas that are marked  Total………… 
 
 
 
 
 
 
 
 
